var title_f33_50_34592="Azelastine: Pediatric drug information";
var content_f33_50_34592=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azelastine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/20/5445?source=see_link\">",
"       Azelastine (nasal): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/19/31026?source=see_link\">",
"       Azelastine (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12929 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-42B5A9483A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34592=[""].join("\n");
var outline_f33_50_34592=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/20/5445?source=related_link\">",
"      Azelastine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/19/31026?source=related_link\">",
"      Azelastine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_50_34593="Central line catheter insertion";
var content_f33_50_34593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Central venous catheter being advanced over guidewire",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    As the catheter is advanced, the guidewire emerges from the distal port. Control should be maintained of both the catheter and the guidewire throughout this process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34593=[""].join("\n");
var outline_f33_50_34593=null;
var title_f33_50_34594="CyA induced arteriolar injury";
var content_f33_50_34594=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing cyclosporine-induced arteriolopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of cyclosporine-induced renal arteriolopathy. There is replacement of smooth muscle cells in the media by proteinaceous material (arrowheads), eventually leading to virtual obliteration of the vascular lumen (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34594=[""].join("\n");
var outline_f33_50_34594=null;
var title_f33_50_34595="Bacteroides fragilis";
var content_f33_50_34595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    <em>",
"     Bacteroides fragilis",
"    </em>",
"    in pleural fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     Bacteroides fragilis",
"    </em>",
"    under high power magnification (1000x) in pleural aspirate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34595=[""].join("\n");
var outline_f33_50_34595=null;
var title_f33_50_34596="Dimenhydrinate: Patient drug information";
var content_f33_50_34596=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dimenhydrinate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/46/12006?source=see_link\">",
"     see \"Dimenhydrinate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/15/11509?source=see_link\">",
"     see \"Dimenhydrinate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dramamine&reg;  for kids [OTC];",
"     </li>",
"     <li>",
"      Dramamine&reg; [OTC];",
"     </li>",
"     <li>",
"      Driminate [OTC];",
"     </li>",
"     <li>",
"      TripTone&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Dimenhydrinate&reg; [OTC];",
"     </li>",
"     <li>",
"      Children&rsquo;s Motion Sickness Liquid [OTC];",
"     </li>",
"     <li>",
"      Dimenhydrinate Injection;",
"     </li>",
"     <li>",
"      Dinate&reg; [OTC];",
"     </li>",
"     <li>",
"      Gravol IM;",
"     </li>",
"     <li>",
"      Gravol&reg; [OTC];",
"     </li>",
"     <li>",
"      Jamp-Dimenhydrinate [OTC];",
"     </li>",
"     <li>",
"      Nauseatol [OTC];",
"     </li>",
"     <li>",
"      Novo-Dimenate [OTC];",
"     </li>",
"     <li>",
"      PMS-Dimenhydrinate [OTC];",
"     </li>",
"     <li>",
"      Sandoz-Dimenhydrinate [OTC];",
"     </li>",
"     <li>",
"      Travel Tabs [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help motion sickness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dimenhydrinate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695834",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before travel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12385 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34596=[""].join("\n");
var outline_f33_50_34596=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160747\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160748\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024102\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024101\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024106\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024107\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024109\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024104\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024105\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024110\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024111\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/46/12006?source=related_link\">",
"      Dimenhydrinate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/15/11509?source=related_link\">",
"      Dimenhydrinate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_50_34597="Pulse wave Doppler COPD constr";
var content_f33_50_34597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Pulse-wave Doppler distinguishes between constrictive pericarditis and chronic obstructive pulmonary disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 222px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with chronic obstructive pulmonary disease (COPD) the pulse-wave Doppler echocardiogram shows pronounced respiratory variation in superior vena caval (SVC) blood flow velocity (red arrows, panel A), which is not seen in constrictive pericarditis. In contrast, the mitral flow velocity (panel B) shows a similar respiratory variation (E wave, black arrows) in COPD and constrictive pericarditis. Recording SVC blood flow velocity is therefore a simple way to distinguish pulsus paradoxus due to constrictive pericarditis from that due to COPD.",
"    <div class=\"footnotes\">",
"     S: systole; D: diastole.; ins: inspiration; exp: expiration.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Boonyaratevej, S, Oh, JK, Tajik, AJ, et al. J Am Coll Cardiol 1998; 32:2043. Copyright &copy; 1998 American College of Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34597=[""].join("\n");
var outline_f33_50_34597=null;
var title_f33_50_34598="Prost intraepithel neopl light";
var content_f33_50_34598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    High grade prostatic intraepithelial neoplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low-magnification (left panel) and high-magnification (right panel) photomicrographs of high grade PIN. The low magnification view demonstrates the presence of pseudostratified neoplastic epithelial cells in benign-looking large glands. In the high-magnification view, the presence of prominent nuclear atypia (arrows) can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ximing Yang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34598=[""].join("\n");
var outline_f33_50_34598=null;
var title_f33_50_34599="Diagnosis of giant cell (temporal) arteritis";
var content_f33_50_34599=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of giant cell (temporal) arteritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34599/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34599/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34599/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34599/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34599/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34599/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34599/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/50/34599/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell arteritis (GCA) is a chronic vasculitis of large- and medium-sized vessels. The mean age at diagnosis is approximately 72 years, and the disease essentially never occurs in individuals younger than 50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/1\">",
"     1",
"    </a>",
"    ]. Among individuals older than 50, the prevalence of GCA has been estimated to be 1 in 500 individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although GCA is characteristically a systemic illness and although vascular involvement may be widespread, symptomatic blood vessel inflammation most frequently involves the cranial branches of the arteries that originate from the aortic arch. The most feared complication of GCA, visual loss, is one potential result of the cranial arteritis associated with this disease.",
"   </p>",
"   <p>",
"    The diagnosis of GCA will be reviewed here. The pathogenesis, clinical manifestations, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8166?source=see_link\">",
"     \"Pathogenesis of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of GCA should be considered in a patient over the age of 50 who complains of or is found to have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      New headaches",
"     </li>",
"     <li>",
"      Abrupt onset of visual disturbances",
"     </li>",
"     <li>",
"      Symptoms of polymyalgia rheumatica",
"     </li>",
"     <li>",
"      Jaw claudication",
"     </li>",
"     <li>",
"      Unexplained fever or anemia",
"     </li>",
"     <li>",
"      High erythrocyte sedimentation rate (ESR)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      high serum C-reactive protein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The manifestations of GCA are protean and highly variable from patient to patient. In addition, some symptoms are transient, demonstrating a tendency to appear, subside, and sometimes return before the start of treatment. As a result, patients in whom the disease is suspected should be questioned carefully about both current and recent symptoms compatible with GCA.",
"   </p>",
"   <p>",
"    If there is sufficient suspicion of GCA based upon the history, physical examination, and laboratory features, a temporal artery biopsy should be performed. In addition to temporal artery biopsy, certain imaging studies (conventional angiography, Doppler ultrasound, magnetic resonance (MR)",
"    <span class=\"nowrap\">",
"     imaging/MR",
"    </span>",
"    angiography, and positron emission tomography [PET]) may also be useful in the assessment of patients with possible GCA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Temporal artery biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporal artery biopsy should be performed in all patients suspected of GCA (",
"    <a class=\"graphic graphic_picture graphicRef57876 \" href=\"mobipreview.htm?16/56/17289\">",
"     picture 1",
"    </a>",
"    ). Patients who manifest only symptoms of polymyalgia rheumatica (PMR) do not require biopsy. However, such patients should be questioned carefully about headache, jaw or arm claudication, visual symptoms, and any unusual pain in the face, throat, or tongue, any of which would suggest the possibility of GCA.",
"   </p>",
"   <p>",
"    Although temporal artery biopsy can be deferred in PMR when no symptoms or signs of GCA are present, close follow-up is important because a small proportion of such patients has or evolves to GCA within several months despite low-dose glucocorticoid therapy for PMR. This was illustrated in a prospective study of 287 patients with GCA in which only 3 of 68 patients (4.4 percent) with a clinical diagnosis of &ldquo;pure&rdquo; PMR had positive findings on temporal artery biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Temporal artery biopsies are generally obtained on an outpatient basis under local anesthesia in a surgical procedure suite or operating room. The technique of temporal artery biopsy, including the decision for unilateral or bilateral biopsy, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37912?source=see_link\">",
"     \"Temporal artery biopsy technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Yield of first biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporal artery biopsy remains the best test for GCA but is imperfect. This was illustrated in a Mayo Clinic study of all 134 residents of Olmsted County, Minnesota who underwent temporal artery biopsies between 1965 and 1980 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/4\">",
"     4",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The temporal artery biopsy was unilateral in 70 and bilateral in 64. The median length to temporal artery tissue obtained was 3.5 and 6.7 cm for unilateral and bilateral biopsies, respectively.",
"     </li>",
"     <li>",
"      Forty-six of the 134 patients had evidence of GCA on temporal artery biopsy (34 percent). This one-to-two ratio of positive to negative biopsies is typical of most published studies, including a later and larger series from the Mayo Clinic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      GCA was eventually diagnosed by repeat biopsy, autopsy, or clinical grounds in 8 of the 88 patients with negative biopsies (9 percent).",
"     </li>",
"     <li>",
"      Thus, 54 patients had GCA, which was detected in 46 on initial temporal artery biopsy (sensitivity 85 percent). In addition, the biopsy correctly predicted the need for glucocorticoid therapy in 126 patients (46 true positive and 80 true negative), which represents 94 percent accuracy. The sensitivity of unilateral biopsies and of biopsies performed at centers not expert in this procedure is undoubtedly lower.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the later report from the Mayo Clinic, the predictive value for a positive temporal artery biopsy increased significantly in patients with specific manifestations of GCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/5\">",
"     5",
"    </a>",
"    ]. In particular, the presence of jaw claudication had a positive predictive value of 78 percent; higher values were noted in those who had jaw claudication plus new headache, scalp tenderness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Explanations for negative biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative temporal artery biopsies may have several explanations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has GCA, but the biopsy missed the area of vascular pathology. This may occur through sampling error due to skip lesions, biopsy of the wrong temporal artery in patients who underwent unilateral biopsy, or attainment of too small a sample (&lt;2 cm).",
"     </li>",
"     <li>",
"      The patient has GCA but has a disease phenotype not associated with cranial arteritis. The most common form of GCA involves the cranial arteries, but other phenotypes exist. One such variant is characterized by involvement of the great vessels and a high likelihood of sparing the temporal arteries (58 percent sensitivity of temporal artery biopsy in a series of 74 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/6\">",
"       6",
"      </a>",
"      ]. Patients with this phenotype may develop upper extremity claudication because of subclavian and axillary artery disease (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73553 \" href=\"mobipreview.htm?6/12/6343\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The patient does not have GCA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Biopsy of other arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although GCA is sometimes called &ldquo;temporal&rdquo; arteritis, the temporal arteries are biopsied in this disease not because they are the focus of GCA (arteritis within the temporal arteries does not lead to blindness) but because they are the blood vessels most easily accessible for diagnosis. If the temporal arteries are not abnormal on examination but if the occipital or facial arteries are, then those other arteries can also be biopsied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37912?source=see_link&amp;anchor=H17025549#H17025549\">",
"     \"Temporal artery biopsy technique\", section on 'Alternative biopsy sites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Initiating glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scheduling of the biopsy should NOT interfere with the start of glucocorticoid therapy when there is a significant concern about the possibility of GCA. Resolution of the inflammatory infiltrate in GCA occurs slowly after the start of treatment, and it is possible to make an accurate diagnosis several weeks or even months after the start of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37912?source=see_link&amp;anchor=H1315277#H1315277\">",
"     \"Temporal artery biopsy technique\", section on 'Glucocorticoid therapy and timing of biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Predicting results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mathematical models, based upon clinical and laboratory data that suggest a clinical diagnosis of GCA, have not been successful in predicting a positive temporal artery biopsy. However, in a second report of 535 patients with temporal artery biopsies from the Mayo Clinic, the following combination of findings correlated with a 95 percent probability of a negative temporal artery biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A normal or mildly elevated ESR (less than 40",
"      <span class=\"nowrap\">",
"       mm/hour)",
"      </span>",
"     </li>",
"     <li>",
"      Absence of jaw claudication",
"     </li>",
"     <li>",
"      Absence of temporal artery tenderness",
"     </li>",
"     <li>",
"      The presence of synovitis, which suggests an alternative diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Biopsy-negative GCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;What should the clinician do if temporal artery biopsies on both sides are negative? Several points should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient may not have GCA. If the clinical story is equivocal, then alternative diagnoses should be given more weight. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The patient may have GCA involving only the great vessels. Among patients with suggestive symptoms (most often arm claudication), an imaging study should be performed for signs of aortic, subclavian, carotid, or other large-vessel disease. The study of choice would be a magnetic resonance angiogram. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Explanations for negative biopsies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Magnetic resonance imaging/angiography'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      An empiric trial of glucocorticoid therapy may be helpful. Failure of the patient&rsquo;s symptoms to resolve within one week of high-dose glucocorticoids argues strongly against the diagnosis of GCA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the final analysis, some patients with classic clinical presentations for GCA have negative temporal artery biopsies and do not have plausible alternative diagnoses. Such patients are generally treated in the same way as those with positive biopsies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several imaging modalities have been investigated for clinical use in GCA. The potential utility of these agents relates both to diagnosis and, in some cases, to estimation of disease activity. Imaging approaches that may be of value in GCA include magnetic resonance",
"    <span class=\"nowrap\">",
"     imaging/angiography,",
"    </span>",
"    conventional angiography, Doppler ultrasound, and positron emission tomography. Magnetic resonance",
"    <span class=\"nowrap\">",
"     imaging/angiography",
"    </span>",
"    is usually the preferred test",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging/angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance",
"    <span class=\"nowrap\">",
"     imaging/angiography",
"    </span>",
"    <span class=\"nowrap\">",
"     (MRI/A)",
"    </span>",
"    may be used to diagnose large-vessel GCA, particularly in cases of suspected GCA not associated with cranial arteritis. In addition,",
"    <span class=\"nowrap\">",
"     MRI/A",
"    </span>",
"    has at least two other potential uses in GCA, both of which require further investigation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       MRI/A",
"      </span>",
"      may be able to identify regions of temporal artery involvement, thereby either serving as part of a diagnostic algorithm or helping to guide temporal artery biopsy.",
"      <br/>",
"      <br/>",
"      A preliminary study using contrast enhanced MRI in 20 patients with suspected GCA visualized the temporal artery and found abnormal contrast enhancement in all 16 patients with positive temporal artery biopsies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/10\">",
"       10",
"      </a>",
"      ]. Additional study of this technique is needed to define its performance in GCA.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       MRI/A",
"      </span>",
"      may eventually be useful in gauging disease activity and in following the response to treatment in patients with large-vessel GCA. Most studies of this technique have been conducted in Takayasu arteritis, a disease closely related to GCA. Early studies have demonstrated both the promise and the shortcomings of",
"      <span class=\"nowrap\">",
"       MRI/A",
"      </span>",
"      in this regard. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/60/3015?source=see_link\">",
"       \"Treatment of Takayasu arteritis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In one study, 77 electrocardiogram-gated &ldquo;edema-weighted&rdquo;",
"      <span class=\"nowrap\">",
"       MRI/A",
"      </span>",
"      studies were performed on 24 patients with Takayasu arteritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/11\">",
"       11",
"      </a>",
"      ]. Evidence of vessel wall edema was noted in 17 of the 18 studies before the patient was believed to have unequivocally active disease. However, vessel wall edema was also noted in 24 of 43 studies in patients who were believed to be in remission.",
"      <br/>",
"      <br/>",
"      Among the 16 patients in the study who underwent serial",
"      <span class=\"nowrap\">",
"       MRI/A",
"      </span>",
"      studies, six did not have radiologic disease progression despite the presence of vessel edema on consecutive",
"      <span class=\"nowrap\">",
"       MRI/A",
"      </span>",
"      studies, and three developed new lesions at one or more sites in the absence of concurrent edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary,",
"    <span class=\"nowrap\">",
"     MRI/A",
"    </span>",
"    is useful in making the diagnosis of large-vessel GCA and in providing a safe, noninvasive means of assessing changes in vascular anatomy. However, even though vessel wall edema may be the result of an early phase of inflammation, this finding is not always associated with disease activity or with the development of new lesions. As a result,",
"    <span class=\"nowrap\">",
"     MRI/A",
"    </span>",
"    is unreliable as the sole guide to disease activity and to treatment decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Conventional angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional angiography is seldom, if ever, employed for diagnostic purposes in the evaluation of the temporal arteries. An angiographic examination of the aortic arch and its branches may show abnormalities among patients with symptoms or findings of large artery involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, these abnormalities can be detected noninvasively by magnetic resonance angiography. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Magnetic resonance imaging/angiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Conventional angiography retains an important clinical role in one scenario. In GCA patients with large-vessel vasculitis involving all four extremities, peripheral measurements of blood pressure may be unreliable because of proximal occlusions. In this setting, aortography with central aortic pressure measurements may be an important adjunct to patient management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the diagnostic usefulness of ultrasonography for prediction of temporal artery biopsy results are mixed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. Ultrasonographic abnormalities reported in GCA patients include stenoses, occlusions, and the presence of a hypoechoic &ldquo;halo&rdquo; (halo sign) around involved arteries. However, encouraging results from early studies were confounded by the failure to blind ultrasonographers to the patients&rsquo; clinical data.",
"   </p>",
"   <p>",
"    A prospective study of duplex ultrasonography in 86 patients with suspected PMR or GCA who later had temporal artery biopsy found that the sensitivity of halo sign for biopsy proven GCA was only 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/18\">",
"     18",
"    </a>",
"    ]. None of the 15 biopsy-positive patients with temporal arteries that were normal on physical examination had halo signs. Thus, ultrasonography offered little advantage over careful physical examination by experienced clinicians in the diagnosis of GCA.",
"   </p>",
"   <p>",
"    The best estimates of the sensitivity and specificity of ultrasonography for GCA are provided by a 2005 meta-analysis of studies that included a total of 2036 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/19\">",
"     19",
"    </a>",
"    ]. Test performance was affected by the choice of the ultrasonographic features used to determine a positive test. For three sets of ultrasound criteria, the results (sensitivity and specificity, respectively) were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Halo sign &mdash; 69 and 82 percent",
"     </li>",
"     <li>",
"      Stenosis or occlusion &mdash; 68 and 77 percent",
"     </li>",
"     <li>",
"      Halo, stenosis, or occlusion &mdash; 88 and 78 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In light of these findings, further evaluation of the usefulness of ultrasound in GCA is warranted. However, the technique remains highly dependent on the skill of the operator and, even in experienced hands ultrasonography, does not supplant temporal artery biopsy as the critical test in the evaluation of a patient with possible GCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Positron emission tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results using position emission tomography (PET) suggest the presence of subclinical inflammation of the great vessels in some patients with GCA or PMR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In PET studies, inflammation is suggested by increased uptake of a radiolabeled glucose analog, fluorodeoxyglucose (FDG), in blood vessels.",
"   </p>",
"   <p>",
"    Direct evaluation of the temporal arteries is not possible with the whole-body PET techniques because of high uptake of FDG in the brain, because of the small diameter of the temporal artery, and because of the relatively high background of the skin (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73553 \" href=\"mobipreview.htm?6/12/6343\">",
"     image 1",
"    </a>",
"    ). However, PET may be more useful for the evaluation of the great vessels. In an initial study of 25 patients with GCA and 13 patients with PMR, thoracic vascular FDG uptake had a sensitivity of 56 percent for the diagnoses of GCA or PMR and a specificity of 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a follow-up study, the investigators studied 20 patients with GCA and 20 with PMR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/24\">",
"     24",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 20 patients with PMR, vascular FDG uptake was visible in only three, while 18 showed intense shoulder and hip uptake.",
"     </li>",
"     <li>",
"      Among the 20 patients with GCA, 16 had intense FDG uptake in large vessels. At three months, FDG uptake had disappeared or persisted at lower levels in all patients. At six months, there was no further decrease in FDG uptake in the six patients restudied at that time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PET scanning is a promising modality for the study of large-vessel vasculitis, yet many questions remain that must be addressed in future investigations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Should patients with a clinical diagnosis of PMR who demonstrate large-vessel FDG uptake be considered to have GCA (and should they be treated accordingly)?",
"     </li>",
"     <li>",
"      Does persistent FDG uptake predict patients at risk for disease flares?",
"     </li>",
"     <li>",
"      How often is the diagnosis of large-vessel vasculitis confounded by the presence of other inflammatory processes involving large vessels, such as atherosclerosis?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special considerations in some of the major categories of disease in the differential diagnosis of GCA are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Large-vessel vasculitides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic and radiographic findings in GCA and Takayasu arteritis may be indistinguishable (",
"    <a class=\"graphic graphic_table graphicRef68594 \" href=\"mobipreview.htm?35/39/36475\">",
"     table 1",
"    </a>",
"    ). These two disorders are differentiated primarily through differences in the age of the affected patients; GCA almost never occurs in individuals younger than 50, while Takayasu arteritis typically begins before the age of 40 (and frequently much younger). In addition, there are some distinctions between these two diseases in their specific disease complications. As an example, visual loss due to anterior ischemic optic neuropathy is unusual in Takayasu arteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=see_link\">",
"     \"Clinical features and diagnosis of Takayasu arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Small- and medium-vessel vasculitides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain small- and medium-vessel vasculitides can mimic GCA through their shared tendency to cause systemic symptoms. However, there is generally little difficulty in distinguishing GCA from microscopic polyangiitis, granulomatosis with polyangiitis (Wegener&rsquo;s), and polyarteritis nodosa because of the different vascular distributions of these diseases, because of their usually distinctive histopathology, and because of their patterns of organ involvement. In occasional cases, however, these forms of necrotizing vasculitis involve the temporal artery and demonstrate overlapping histopathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Central nervous system vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the histopathology of primary angiitis of the central nervous system can be indistinguishable from that of GCA, the two disorders can be separated by the fact that cranial ischemic events in GCA are usually not caused by intracranial disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25386?source=see_link\">",
"     \"Primary angiitis of the central nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\", section on 'Central nervous system involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nonvasculitic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare cases, nonvasculitic disorders mimic some of the major findings in GCA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jaw or arm claudication can occur in patients with amyloidosis and vascular involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonarteritic anterior ischemic optic neuropathy (NAAION) can mimic many of the features of vision loss in GCA and also tends to occur in older individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34599/abstract/29\">",
"       29",
"      </a>",
"      ]. NAAION is associated with the risk factors of hypertension, diabetes mellitus, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      and related drugs, and the physical examination finding of small optic discs. Other clinical features of GCA and laboratory markers of inflammation, such as an elevated ESR",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C-reactive protein (CRP), are generally absent in NAAION. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27558?source=see_link\">",
"       \"Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20442?source=see_link\">",
"       \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of male sexual dysfunction\", section on 'Visual effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/54/42852?source=see_link\">",
"       \"Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of giant cell arteritis (GCA) should be considered in a patient over the age of 50 who complains of or who is found to have: (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A new headache",
"     </li>",
"     <li>",
"      Abrupt onset of visual disturbances",
"     </li>",
"     <li>",
"      Symptoms of polymyalgia rheumatica",
"     </li>",
"     <li>",
"      Unexplained fever or anemia",
"     </li>",
"     <li>",
"      Elevated erythrocyte sedimentation rate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serum C-reactive protein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporal artery biopsy is the gold standard for the diagnosis of GCA. Negative temporal artery biopsy occurs in up to 40 percent of patients suspected of GCA who are referred for biopsy. For those who have undergone unilateral biopsy, a contralateral biopsy should be performed if the first biopsy is negative. An alternative biopsy site can be considered if bilateral temporal artery biopsy is negative and if disease is strongly suspected clinically. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37912?source=see_link\">",
"       \"Temporal artery biopsy technique\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Scheduling of temporal artery biopsy should never interfere with the start of treatment in a patient with a high likelihood of GCA, since resolution of the inflammatory infiltrate in GCA occurs slowly after the start of treatment and since it is possible to make an accurate diagnosis several weeks or even months after the start of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initiating glucocorticoid therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although Doppler ultrasonography has been studied in some detail in GCA, this technique is highly operator-dependent and does not replace temporal artery biopsy as the gold standard for diagnosis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance",
"      <span class=\"nowrap\">",
"       imaging/angiography",
"      </span>",
"      is useful in the identification of large-vessel disease in GCA. Its utility for identifying abnormalities in the temporal arteries with sufficient precision and in estimating disease activity in large arteries requires further investigation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Magnetic resonance imaging/angiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Positron emission tomography is a promising imaging modality in GCA, but its precise role in the diagnosis and longitudinal management of GCA requires further study. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Positron emission tomography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/1\">",
"      Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002; 287:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/2\">",
"      Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/3\">",
"      Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996; 35:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/4\">",
"      Hall S, Persellin S, Lie JT, et al. The therapeutic impact of temporal artery biopsy. Lancet 1983; 2:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/5\">",
"      Younge BR, Cook BE Jr, Bartley GB, et al. Initiation of glucocorticoid therapy: before or after temporal artery biopsy? Mayo Clin Proc 2004; 79:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/6\">",
"      Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999; 42:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/7\">",
"      Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994; 120:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/8\">",
"      Evans JM, Batts KP, Hunder GG. Persistent giant cell arteritis despite corticosteroid treatment. Mayo Clin Proc 1994; 69:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/9\">",
"      Gabriel SE, O'Fallon WM, Achkar AA, et al. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 1995; 22:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/10\">",
"      Bley TA, Wieben O, Uhl M, et al. High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol 2005; 184:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/11\">",
"      Tso E, Flamm SD, White RD, et al. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002; 46:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/12\">",
"      Evans JM, Bowles CA, Bjornsson J, et al. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 1994; 37:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/13\">",
"      Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975; 83:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/14\">",
"      Pu&eacute;chal X, Chauveau M, Menk&egrave;s CJ. Temporal Doppler-flow studies for suspected giant-cell arteritis. Lancet 1995; 345:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/15\">",
"      Ho AC, Sergott RC, Regillo CD, et al. Color Doppler hemodynamics of giant cell arteritis. Arch Ophthalmol 1994; 112:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/16\">",
"      Schmidt WA, Kraft HE, Vorpahl K, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/17\">",
"      Pfadenhauer K, Weber H. Duplex sonography of the temporal and occipital artery in the diagnosis of temporal arteritis. A prospective study. J Rheumatol 2003; 30:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/18\">",
"      Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis?. Ann Intern Med 2002; 137:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/19\">",
"      Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 2005; 142:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/20\">",
"      Maldini C, D&eacute;pinay-Dhellemmes C, Tra TT, et al. Limited value of temporal artery ultrasonography examinations for diagnosis of giant cell arteritis: analysis of 77 subjects. J Rheumatol 2010; 37:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/21\">",
"      Hunder GG, Weyand CM. Sonography in giant-cell arteritis. N Engl J Med 1997; 337:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/22\">",
"      Blockmans D, Stroobants S, Maes A, Mortelmans L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000; 108:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/23\">",
"      Scheel AK, Meller J, Vosshenrich R, et al. Diagnosis and follow up of aortitis in the elderly. Ann Rheum Dis 2004; 63:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/24\">",
"      Blockmans D. Utility of imaging studies in assessment of vascular inflammation. Cleve Clin J Med 2002; 69 Suppl 2:SII95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/25\">",
"      Kerr GS. Takayasu's arteritis. Rheum Dis Clin North Am 1995; 21:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/26\">",
"      Lie JT. When is arteritis of the temporal arteries not temporal arteritis? J Rheumatol 1994; 21:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/27\">",
"      Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 2007; 62:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/28\">",
"      Lakhanpal S, Li CY, Gertz MA, et al. Synovial fluid analysis for diagnosis of amyloid arthropathy. Arthritis Rheum 1987; 30:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34599/abstract/29\">",
"      Lessell S. Nonarteritic anterior ischemic optic neuropathy: enigma variations. Arch Ophthalmol 1999; 117:386.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8242 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34599=[""].join("\n");
var outline_f33_50_34599=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Temporal artery biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Yield of first biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Explanations for negative biopsies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Biopsy of other arteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Initiating glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Predicting results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Biopsy-negative GCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Magnetic resonance imaging/angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Conventional angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Positron emission tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Large-vessel vasculitides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Small- and medium-vessel vasculitides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Central nervous system vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nonvasculitic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/8242\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8242|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/12/6343\" title=\"diagnostic image 1\">",
"      Left subclavian artery GCA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8242|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/56/17289\" title=\"picture 1\">",
"      Giant cell arteritis light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8242|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/39/36475\" title=\"table 1\">",
"      Giant cell v Takayasu arteritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=related_link\">",
"      Clinical features and diagnosis of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13832?source=related_link\">",
"      Clinical manifestations and diagnosis of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27558?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20442?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8166?source=related_link\">",
"      Pathogenesis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/54/42852?source=related_link\">",
"      Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37912?source=related_link\">",
"      Temporal artery biopsy technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/60/3015?source=related_link\">",
"      Treatment of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34217?source=related_link\">",
"      Treatment of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_50_34600="Corneal abrasions and corneal foreign bodies";
var content_f33_50_34600=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Corneal abrasions and corneal foreign bodies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34600/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34600/contributors\">",
"     Deborah S Jacobs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34600/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34600/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34600/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34600/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34600/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/50/34600/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H436772156\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneal abrasion is the term most often applied to any defect in the corneal surface epithelium. However, this is an inexact use of the term, because it also implies etiology. These abnormalities are more appropriately called \"corneal epithelial defects,\" while corneal abrasion more strictly refers to a defect in the epithelial surface of the cornea that is caused by mechanical trauma to the surface of the eye. Nevertheless, since \"corneal epithelial defect\" is not a term in general usage by patients and providers, we will use both terms interchangeably to refer to corneal epithelial defects of all etiologies.",
"   </p>",
"   <p>",
"    This topic will review the etiology, clinical presentation, diagnosis, and treatment of corneal abrasions. The general approach to a patient with red eye is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneal abrasions can be classified as traumatic, foreign body related, contact lens related, or spontaneous. Spontaneous corneal abrasions are also known as recurrent erosions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A traumatic corneal abrasion is the classic corneal abrasion in which mechanical trauma to the eye results in a defect in the epithelial surface. Traumatic corneal abrasions are often caused by fingernails, paws, pieces of paper or cardboard, make-up applicators, hand tools, branches, and leaves, or by a foreign body that has lodged under the lid.",
"     </li>",
"     <li>",
"      Foreign body related abrasions are defects in the corneal epithelium that are left behind after the removal or spontaneous dislodging of a corneal foreign body. Foreign body abrasions are typically caused by pieces of rust, wood, glass, plastic, fiberglass, or vegetable material that have become embedded in the cornea.",
"     </li>",
"     <li>",
"      Contact lens related abrasions are defects in the corneal epithelium that are left behind after the removal of an over-worn, improperly fitting, or improperly cleaned contact lens. These eyes have suffered a mechanical insult that is not from external trauma, but rather from a foreign body that is associated with specific pathogens.",
"     </li>",
"     <li>",
"      Spontaneous defects in the corneal epithelium may occur with no immediate antecedent injury or foreign body. Eyes that have suffered a previous traumatic abrasion or eyes that have an underlying defect in the corneal epithelium are prone to this problem.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneal abrasions are common, accounting for 12 to 13 percent of new cases seen in two different eye emergency units in the United Kingdom in 1981 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/1\">",
"     1",
"    </a>",
"    ] and in 1995 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/2\">",
"     2",
"    </a>",
"    ]. They are also a frequent presenting problem in general emergency departments. In 1983 at a general hospital emergency department in the United Kingdom, 6 percent of all new cases were eye cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/3\">",
"     3",
"    </a>",
"    ]. Trauma accounted for 66 percent of these or 4 percent of all cases; corneal abrasions or corneal or conjunctival foreign bodies accounted for 80 percent of the eye trauma cases or 3 percent of all cases. A sampling of diagnoses in family and general clinicians', internists', and pediatricians' offices in the United States in 1985 found that eye complaints constitute 2 percent of all patient visits; traumatic conditions and foreign bodies were the reason for 8 percent of these visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Workplace eye injuries cause significant avoidable (with protective eyewear) morbidity and lost productivity. A study of eye injuries in a major United States automotive corporation found an annual incidence of 15 eye injuries per 1000 employees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/5\">",
"     5",
"    </a>",
"    ]. The eye injuries comprised 6 percent of total injuries, and corneal foreign bodies and abrasions were 87 percent of the eye injuries. One-third of eye injuries resulted in the inability of workers to resume normal duties for at least one day. In another report, most patients with corneal foreign bodies did not take more than one day off work, and up to 30 percent sought treatment outside of working hours to avoid lost time from work [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with corneal abrasions of all types have the same clinical presentation. The corneal epithelium is richly innervated with sensory pain fibers from the trigeminal nerve. Thus, patients typically complain of excruciating eye pain and an inability to open the eye due to foreign body sensation. Often patients are too uncomfortable to work, drive, or read, and the pain frequently precludes sleep. Multiple attempts by the patient to \"wash out\" the eye can further disrupt the epithelial surface.",
"   </p>",
"   <p>",
"    A complaint of eye pain and objective evidence of foreign body sensation (eg, observation that the patient is keeping the affected eye shut) together are highly suggestive of a pathologic process of the cornea, although no formal studies of the sensitivity and specificity of these findings have been performed. The exception is patients with dysfunction of cranial nerve V due to trauma, tumor, or prior infection with Herpes Simplex or Varicella Zoster (shingles); these individuals may have corneal defects with no pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient who complains of severe eye pain with foreign body sensation preventing opening of the eye generally can be presumed to have a corneal epithelial defect. The provider must then first rule out first penetrating trauma, and second an infectious infiltrate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history may allow distinction between the subtypes of abrasion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with traumatic abrasion will be able to recall direct trauma to the globe followed almost immediately by foreign body sensation.",
"     </li>",
"     <li>",
"      Patients with a foreign body may or may not recall an episode with material falling or flying into the eye since, depending upon the type and size of the foreign body, symptoms may not be immediate, or they may be immediate, then abate for awhile, then recur. If the foreign body entered the eye at high velocity, as may be the case when using a grinding machine or from metal striking metal, the examiner must consider the possibility of a penetrating eye injury and modify the subsequent examination as clinical findings require.",
"     </li>",
"     <li>",
"      Other relevant points of history include whether the episode is associated with contact lens wear or, in the case of apparently spontaneous abrasions, whether there is history of prior traumatic abrasion. Patients with recurrent erosion syndrome tend to awaken in the middle of the night with searing eye pain, or they develop the pain upon first awakening in the morning with attempt to open the eyes. This description is diagnostic of recurrent erosion syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Eye examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Excluding penetrating trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults in whom the history raises the possibility of penetrating trauma, and in children in whom the history may be unreliable, the initial examination must exclude penetrating trauma.",
"   </p>",
"   <p>",
"    If the patient is unable to voluntarily open the eye, the lids are gently pulled apart or the upper lid lifted, avoiding pressure on the globe. The pupil should be confirmed to be round and central. The anterior chamber should appear grossly clear, deep, and of normal contour. In corneal abrasion, the pupil is typically small (reactive miosis). Pupillary constriction in response to light may be difficult to detect in the presence of reactive miosis.",
"   </p>",
"   <p>",
"    A large nonreactive pupil or an irregular pupil suggest injury to the pupillary sphincter from penetrating trauma or significant blunt trauma. These findings warrant further evaluation.",
"   </p>",
"   <p>",
"    Any patient with blood (hyphema) or pus (hypopyon) in the anterior chamber should be examined that day by an ophthalmologist. Any patient with evidence of extruded ocular contents, which typically appear as a jelly-like substance with pigmented or bloody debris, requires placement of a metal or plastic shield to protect the open globe and emergent referral to an ophthalmologist for surgical repair. The shield is positioned so as to protect the eye without pressure on the globe. If a shield is not available, it may be possible to construct a temporary shield with other materials such as a small paper cup and tape.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Visual acuity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual acuity may be normal if the abrasion is away from the visual axis. It might be slightly subnormal, in the",
"    <span class=\"nowrap\">",
"     20/25",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    range, if the abrasion is in the visual axis, or it might be substantially subnormal (as low as",
"    <span class=\"nowrap\">",
"     20/400)",
"    </span>",
"    if the abrasion is in the visual axis and there is corneal edema.",
"   </p>",
"   <p>",
"    Corneal edema tends to develop in abrasions that have been present for more than 12 hours after the patient continually rubs or presses on the eye in response to pain. Corneal edema causes the cornea to have a hazy gray appearance rather than a distinct infiltrate. Referral to an ophthalmologist is warranted if the primary care provider is not certain that he or she can distinguish corneal haze from an infiltrate in the patient with an \"abrasion\" who has substantially reduced acuity; an infectious infiltrate can have sight-threatening consequences if not diagnosed, treated, and monitored properly. A corneal infiltrate may not affect acuity if it is out of the visual axis; thus, acuity alone is not sufficient to distinguish infiltrate from haze.",
"   </p>",
"   <p>",
"    Acuity should be measured without the aid of a topical anesthetic. For the rare patient who is too uncomfortable to cooperate with this measurement, a penlight examination to confirm that there is no evidence of penetrating trauma should be performed, and then one drop of topical anesthetic (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/57/2963?source=see_link\">",
"     proparacaine",
"    </a>",
"    0.5 percent solution) may be instilled to facilitate the measurement of visual acuity and the subsequent examination. The patient will obtain drastic relief within 10 seconds of the instillation and will likely ask for additional doses after the drop wears off in 10 to 20 minutes. Topical anesthetics should not be used routinely as they can be toxic to the epithelium and retard healing, ultimately increasing the risk of infection and scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Pain control'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Penlight and fundoscopic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pupils can be assessed with the penlight examination. However, the pupil is sometimes quite small in a patient with an abrasion, making it difficult to detect a light response.",
"   </p>",
"   <p>",
"    The penlight examination will reveal mild injection if the abrasion is more than an hour or two old; there may be ciliary flush if it is more than several hours old. With ciliary flush, injection is most marked at the limbus (where the cornea undergoes transition to the sclera) and then diminishes toward the equator.",
"   </p>",
"   <p>",
"    There should be no discharge other than tears, and no infiltrate or corneal opacity. The edges of the abrasion can usually be detected by the disruption that it causes to the corneal light reflex. A foreign body also often can be detected at this time by direct visualization with the penlight.",
"   </p>",
"   <p>",
"    The chamber should have a normal contour and the pupil should be round. A flat chamber, a chamber full of blood (hyphema), or an irregular pupil increases suspicion of a penetrating eye injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/10/38057?source=see_link\">",
"     \"Traumatic hyphema: Clinical features and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A fundoscopic examination should be attempted, at least to confirm a red reflex. However, visualization of fundus detail may be difficult due to a small pupil and photophobia. Eye motility also should be assessed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44486?source=see_link\">",
"     \"Slit lamp examination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fluorescein examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     Fluorescein",
"    </a>",
"    examination should be performed to confirm the diagnosis only after completion of the penlight and fundus examination, and after a presumptive diagnosis of corneal abrasion is made based upon the history, above physical signs, and lack of signs of other disorders. Earlier instillation of dye may interfere with visual acuity measurement and visualization of the anterior segment and fundus. Fluorescein examination should be considered confirmatory rather than diagnostic.",
"   </p>",
"   <p>",
"    The examination is performed as follows. The lower lid is pulled down, and a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    impregnated paper strip is moistened with saline or topical anesthetic, allowing a drop to run off into the eye or the inferior cul-de-sac. When the patient blinks, the dye is distributed over the ocular surface. Alternatively, the strip is gently swiped against the bulbar or tarsal conjunctiva below the cornea and the patient is allowed to blink to distribute the fluorescein.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     Fluorescein",
"    </a>",
"    stains basement membrane, which is exposed in the area of the epithelial defect. The affinity is quite high, so very little fluorescein is necessary. The stained abrasion can often be seen as yellowish with the naked eye. Visualization is enhanced by the use of a cobalt blue filter (available on any ophthalmoscope or slit lamp) or a Wood's lamp. Foreign bodies may not stain, although the exposed edge of epithelium at the edge of the foreign body typically does. Clinicians who are examining with a slit lamp can look for a Seidel sign (streaming of fluorescein caused by leaking aqueous humor), which, if present, indicates penetrating trauma.",
"   </p>",
"   <p>",
"    The staining defect can appear linear or geographic depending upon the nature of the abrading insult (",
"    <a class=\"graphic graphic_picture graphicRef77817 \" href=\"mobipreview.htm?20/21/20816\">",
"     picture 1",
"    </a>",
"    ). A branching pattern suggests herpes simplex virus infection (",
"    <a class=\"graphic graphic_picture graphicRef86913 \" href=\"mobipreview.htm?10/57/11152\">",
"     picture 2",
"    </a>",
"    ). A nearly healed abrasion may have a branching appearance as the defect closes in, but this patient will have resolution of symptoms in 24 hours while the patient with a herpes dendrite will not. A further distinction is that the patient with a herpes dendrite can report no specific antecedent injury, and there may be a history of prior episodes of herpes keratitis. Skilled ophthalmologists sometimes have difficulty distinguishing a herpes dendrite from a healing abrasion (pseudo-dendrite) and will occasionally monitor for 24 to 48 hours to distinguish the two. An &ldquo;abrasion&rdquo; with branching pattern, particularly one that is failing to improve over 24 to 48 hours, warrants ophthalmic evaluation.",
"   </p>",
"   <p>",
"    After the diagnosis of abrasion is confirmed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    , it is good practice to flip the upper lid to rule out the presence of a retained foreign body. Retained foreign bodies typically cause an abrasion with a characteristic appearance of multiple parallel vertical lines at the upper edge of the cornea, but the inexperienced observer may not be able to distinguish this pattern from that of any other abrasion. If the lid foreign body has been present for several hours or if time has elapsed since the instillation of fluorescein, the parallel lines may become contiguous, confounding even the experienced observer.",
"   </p>",
"   <p>",
"    Contact lens associated staining defects tend to be round and central, sometimes encompassing the entire cornea. Typically there is punctate breakdown that has become contiguous. The punctate pattern may be apparent immediately upon instillation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    , but will be more difficult to discern as the fluorescein diffuses through the cornea.",
"   </p>",
"   <p>",
"    Defects from recurrent erosions have no specific diagnostic appearance. Sometimes a mobile flap of epithelium can be visualized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment of corneal abrasions is summarized in an algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef80921 \" href=\"mobipreview.htm?37/29/38354\">",
"     algorithm 1",
"    </a>",
"    ). Treatment options vary based on the subtype of corneal abrasion.",
"   </p>",
"   <p>",
"    Patients may have had severe pain for several hours by the time they seek care. They are visibly uncomfortable, pacing or rocking or rubbing the eye, and they can be disruptive to a waiting room. During the initial triage period, they should be offered a darkened room in which to wait, asked to wait quietly with the eyes closed, and encouraged not to rub the eye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Traumatic and foreign body abrasions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patching and administration of topical antibiotics and cycloplegics has been the mainstay of therapy for decades, along with daily follow-up until the eye is healed. Animal studies suggest that tetanus prophylaxis is warranted for penetrating eye injuries, but not for corneal abrasions or foreign bodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/8\">",
"     8",
"    </a>",
"    ]. While patching has been the subject of many controlled trials, the use of topical antibiotics and cycloplegics has not been subject to the same critical evaluation. There are also no data to indicate which patients should be followed, how frequently, or for how long.",
"   </p>",
"   <p>",
"    Patients who have a corneal abrasion with infected material (farm instruments, vegetable matter) are at risk for developing bacterial keratitis; this is the most common cause of bacterial keratitis among rural agricultural laborers in undeveloped countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients in whom such a mechanism is known or suspected should probably be monitored daily for corneal infiltrate or ulceration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Topical antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be treated with topical antibiotics to prevent superinfection although, as previously mentioned, this practice has never been rigorously studied. An ointment is better than drops because it functions as a lubricant, in theory reducing disruption of the remaining and newly generated epithelium.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    ointment (Ilotycin) is a good choice, used four times daily for three to five days. For patients who insist on a drop rather than an ointment,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/57/33680?source=see_link\">",
"     sulfacetamide",
"    </a>",
"    10 percent,",
"    <span class=\"nowrap\">",
"     polymyxin/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"      trimethoprim",
"     </a>",
"    </span>",
"    (Polytrim),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (Ciloxan), or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    (Ocuflox) four times daily for three to five days are reasonable choices. Aminoglycosides should be avoided, except in the case of contact lens-related abrasions, since they can be toxic to the epithelium. Preparations containing steroids are contraindicated; they slow epithelial healing and reduce host resistance to superinfection.",
"   </p>",
"   <p>",
"    The optimal duration and frequency of antibiotic therapy have never been subjected to outcome analysis. It is reasonable to decrease the frequency to twice daily once the foreign body sensation has resolved and to discontinue therapy entirely if the eye is symptom free for 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Patching",
"    </span>",
"    &nbsp;&mdash;&nbsp;In theory, a pressure patch promotes epithelial proliferation and migration by keeping the lid lowered and stationary over the epithelial defect; such pressure is also thought to relieve pain. The purpose of patching is not to exclude light or dirt.",
"   </p>",
"   <p>",
"    Patients are often resistant to eye patching. Some find the patch irritating and take it off prior to the prescribed amount of wear. Patching also results in loss of depth perception and restriction of visual fields that can interfere with ambulation, particularly negotiating stairs and curbs. Patients shouldn't drive with a patch. Patients who are monocular or amblyopic and have an abrasion in their \"good\" eye will be incapacitated by patching.",
"   </p>",
"   <p>",
"    In addition to the problems with patching listed above, controlled studies have not found patching to improve the rate of healing or comfort in patients with traumatic or foreign body abrasions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. One study, for example, evaluated 201 patients with noninfected, noncontact lens related, traumatic or foreign body related corneal abrasions who were followed daily after receiving topical antibiotics and mydriatics and after being randomly assigned to receive either a pressure patch or no patch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with traumatic corneal abrasions (n=120) healed significantly faster, had less pain, and fewer reports of blurred vision when they were not wearing a patch. The amount of photophobia, tearing, and foreign body sensation were similar between the patch and no patch groups. In patients with corneal abrasions due to removal of foreign bodies (n=81), healing also occurred significantly faster and was associated with less pain in those not wearing a patch. There was no difference in the amount of photophobia, tearing, foreign body sensation, or blurred vision. Meta-analyses of trials studying the use of eye patches came to similar conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the lack of proven benefit with patching, the possibility of improper patching, and potential patient discomfort and inconvenience suggest that it is reasonable to treat corneal abrasions without an eye patch. There may be some exceptions to this general rule; in particular, patients with large abrasions occupying more than one-half of the corneal surface may obtain pain relief with patching.",
"   </p>",
"   <p>",
"    If the decision is made to apply a pressure patch, proper application is critical. A properly applied patch precludes blinking. Improper application may allow the patient to blink under the patch or worse, abrade the cornea further.",
"   </p>",
"   <p>",
"    Two gauze eye pads and three strips of tape are required for patching. Antibiotic ointment is applied to the eye by instilling a small amount",
"    <span class=\"nowrap\">",
"     (1/2\"",
"    </span>",
"    to 1\" ribbon) in the inferior cul-de-sac. One pad is folded in half. The patient is asked to close both eyes",
"    <strong>",
"     gently",
"    </strong>",
"    . There should be no squeezing of the orbicularis muscles. The folded patch is used to occupy the space over the globe in the orbit and apply pressure to the globe. The second pad is then placed over the folded pad. The patient or an assistant is asked to apply firm pressure to the second pad, while it is being taped firmly with the three strips of tape. These strips are most effective if place obliquely from the midline over the nose toward the cheekbone. The patient is then asked to open the eyes and report if the lid under the patch can be raised. If it can then the patch has not been applied successfully and must be redone. The patch is left in place overnight, and no more than 24 hours. A patch that is worn too long may interfere with the diagnosis of infection because the patient cannot monitor vision and discharge.",
"   </p>",
"   <p>",
"    There is no role for a \"pirate's patch\" in the treatment of corneal abrasions. These are black fabric patches on an elastic band sold at pharmacies. These patches are designed to cover an unsightly or light sensitive eye with no useful vision; they should not be used in cases of corneal abrasion. They do not keep the lid down as a properly applied pressure patch does, and the elastic applies tension to the patch in a band that can press on the cornea, increasing corneal edema and interfering with healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four approaches to pain control for corneal abrasion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mechanical",
"     </li>",
"     <li>",
"      Cycloplegic",
"     </li>",
"     <li>",
"      Systemic",
"     </li>",
"     <li>",
"      Topical analgesia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any or all can be used in a particular case. As mentioned above, however, mechanical pain relief with patching is usually not useful except possibly in patients with large abrasions. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Patching'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cycloplegics are parasympatholytic drops that inhibit the miotic (pupil-constricting) response to light; it is this response to light that causes the ache and photophobia of corneal abrasion. These drops do not relieve foreign-body sensation, per se. Cycloplegics make the pupil large, causing glare, and also block accommodation, thereby interfering with near work such as reading.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/34/24100?source=see_link\">",
"     Cyclopentolate",
"    </a>",
"    (Cyclogyl) 0.5 or 1 percent has the shortest duration of action, but still lasts for 24 to 36 hours. Thus, patients with small abrasions that heal overnight may find that the side effects outweigh the benefits. Patients with large abrasions who are particularly photophobic can be treated for up to 48 hours with cyclopentolate 0.5 to 1 percent twice daily or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/43/35508?source=see_link\">",
"     homatropine",
"    </a>",
"    2.5 to 5 percent daily. Longer acting drugs such as topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    are used by ophthalmologists for iritis and severe cases of ocular disease; these drugs can interfere with accommodation for weeks and should not be used to treat abrasions.",
"   </p>",
"   <p>",
"    Systemic therapy with opioids can be very helpful for patients with corneal abrasion. Most abrasions smaller than one-half of the corneal surface will heal overnight if the lid is down and there is no rubbing or squeezing. Opioids can help accomplish this goal by relieving pain and allowing the patient a comfortable night of sleep. A reasonable regimen for adults is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/51/9016?source=see_link\">",
"     oxycodone-acetaminophen",
"    </a>",
"    <span class=\"nowrap\">",
"     5/325",
"    </span>",
"    (1 to 2 tablets for initial pain relief, to be repeated one time after four hours if the patient awakens from sleep due to pain). Nonsteroidal antiinflammatory (NSAID) ophthalmic solutions (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    ) may also provide some pain relief and limit the need for opioids, without apparent adverse effects upon healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The use of topical anesthesia for pain relief is controversial because animal studies suggest that topical anesthesia can delay corneal epithelial healing, particularly with repeated applications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition to delayed wound healing, anesthetic abuse can also result in \"addiction,\" in which the patient persists in use of the drops, sometimes surreptitiously, for a painful, non-healing surface. This can ultimately lead to ulceration, perforation, scarring, or blindness.",
"   </p>",
"   <p>",
"    However, according to some studies in humans, dilute solutions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/57/2963?source=see_link\">",
"     proparacaine",
"    </a>",
"    (0.05 percent, versus standardly available 0.5 percent) provide analgesia without impairing healing after several days of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. This had led some clinicians to use dilute proparacaine to treat corneal abrasions, although it has not been approved by the US Food and Drug Administration for this indication. In one trial of 33 patients presenting with corneal injury, those randomly assigned to dilute proparacaine drops (0.05 percent, two to four drops as needed) reported improved pain control compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/19\">",
"     19",
"    </a>",
"    ]. There were no signs of delayed wound healing or ocular complications in either group at five-day follow-up. However, this trial was underpowered to detect differences in adverse effects, and long-term follow-up was not reported. The administration of proparacaine in this study required a ten-fold dilution under sterile conditions and close follow-up by an ophthalmologist. Further studies are needed to determine the safety of dilute topical anesthetic prior to widespread use. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Visual acuity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Foreign body removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a corneal foreign body is detected, an attempt can be made to remove it by irrigation. This is particularly helpful in the case of multiple superficial foreign bodies. An attempt can then be made to remove the foreign body with a swab after the instillation of topical anesthetic, using direct visualization.",
"   </p>",
"   <p>",
"    Foreign bodies under the lid should be removed after flipping the lid. If the foreign body cannot be dislodged by irrigation or with a swab, the patient should be treated by an individual trained and supervised in the use of instruments to dislodge foreign bodies off the ocular surface. This procedure is performed using magnification (usually a slit lamp, sometimes loupes) and a metal instrument. Topical anesthetic is instilled in the eye. The instrument used can be a 25G needle or a foreign body spud. Appropriate technique, including patient instruction, tangential approach to the cornea, and stabilization of the hand on the zygoma, is required to insure patient cooperation and to avoid further injury to the cornea.",
"   </p>",
"   <p>",
"    Typically, ophthalmology residents and residents in emergency medicine and in family practice receive formal training in the removal of corneal foreign bodies. Those without formal training should not approach the globe with sharp instruments; an appropriately trained clinician should be consulted if removal with a swab is unsuccessful. The foreign body should be removed within 24 hours. The patient should be treated in the meantime with a topical antibiotic ointment (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ) four times a day and no patch.",
"   </p>",
"   <p>",
"    After removal of a foreign body containing iron there is often a residual rust ring and reactive infiltrate. Patients with rust ring should be treated as patients with corneal abrasions. The rust ring itself is not harmful and will usually resorb gradually. If there is failure of the epithelium to heal after 2-3 days, debridement of rust ring can be considered by clinicians trained in the use of instruments at the slit lamp. Removal of rust ring on a routine basis at time of foreign body removal is not recommended because of potential damage to Bowman&rsquo;s membrane and resultant scarring.",
"   </p>",
"   <p>",
"    It is not possible to clinically distinguish infected from non-infected corneal bodies. In one study, 14 percent of 63 removed foreign bodies (the majority of which were metallic) cultured positive; the major pathogen was coagulase negative Staphylococcus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/22\">",
"     22",
"    </a>",
"    ]. Neither the mechanism of injury, the presence of a rust ring, nor the time present in the cornea allowed prediction of the presence or absence of infection. Nevertheless, foreign bodies need not be sent for culture; all patients with foreign body associated abrasions are treated with empiric broad spectrum antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Contact lens related abrasions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with contact lens related abrasions are treated differently from patients with the other types of abrasions because of their susceptibility to infectious keratitis. Contact lens wear is the most common cause of infectious keratitis in industrialized nations. Extended wear (sleeping with lenses in place) increases the risk of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/9,23\">",
"     9,23",
"    </a>",
"    ]. The increased risk is thought to be multifactorial and related to alterations in pathogen adhesion to the ocular surface due to the mechanical presence of the contact lens, adhesion of pathogens to the lens itself, colonization of solutions and lens cases with pathogens, and the warmer and more humid environment at the ocular surface created by the presence of a lens, particularly when the eye is closed, as when patients sleep with their lenses in. Infectious pseudomonas keratitis is a fulminant ulcerative necrotizing process that can result in corneal melting and perforation within 24 hours. Even if perforation and vision loss on that basis is averted, there is often permanent corneal scarring that requires corneal transplantation.",
"   </p>",
"   <p>",
"    Because of this risk of infection, patients with contact lens associated corneal abrasions should",
"    <strong>",
"     never be patched",
"    </strong>",
"    . Patching of what appeared to be sterile abrasions can lead to sight-threatening infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/24\">",
"     24",
"    </a>",
"    ]. Increased temperature under the patch is theorized to be a contributing factor, as well as the presence of the patch itself, which interferes with the patient's ability to monitor for clinical deterioration.",
"   </p>",
"   <p>",
"    Contact lens wearers who present with a corneal epithelial defect should be examined with the penlight to look for a corneal infiltrate, which is a white spot or opacity, or an ulcer (",
"    <a class=\"graphic graphic_picture graphicRef75303 graphicRef55332 \" href=\"mobipreview.htm?9/63/10231\">",
"     picture 3A-B",
"    </a>",
"    ), which is surface breakdown, thinning, or necrosis that occurs in an area of infiltration. Any patient with such a finding should be seen by an ophthalmologist",
"    <strong>",
"     that day",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    If no infiltrate is seen and an epithelial defect is present, the patient should be treated with a topical antibiotic that is effective against Pseudomonas. Reasonable choices are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    (Ocuflox),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (Ciloxan), or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    (Tobrex) drops or ointment, to be used four times a day.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/57/33680?source=see_link\">",
"     Sulfacetamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    are not satisfactory antibiotic choices because they do not provide adequate pseudomonas coverage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34600/abstract/23\">",
"     23",
"    </a>",
"    ]. Cycloplegia and opioids for pain relief can be used as needed as for traumatic abrasions (see above). The patient should be checked in 24 hours to confirm the absence of a corneal infiltrate or ulcer (",
"    <a class=\"graphic graphic_picture graphicRef75303 graphicRef55332 \" href=\"mobipreview.htm?9/63/10231\">",
"     picture 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Recurrent erosion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with recurrent erosion syndrome are treated the same as patients with traumatic abrasions. However, these individuals are often exquisitely symptomatic to even the smallest epithelial disruption. My clinical experience is that they do better with frequent application (every one to two hours) of ointment at the first suggestion of symptoms (either an antibiotic such as Ilotycin or over-the-counter lubricant such as Refresh PM or Lacrilube), and opioid if needed, rather than patching. Lubricant ointment therapy should be continued at bedtime for months after acute symptoms have resolved as a prophylactic regimen.",
"   </p>",
"   <p>",
"    Recurrent erosions that are particularly large or show no signs of healing in 24 hours should be referred to an ophthalmologist who may debride flaps of epithelium and may choose to use an extended wear contact lens as a bandage. Cases that don't respond to these measures can be treated with stromal micropuncture or phototherapeutic keratectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CHILDREN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     History and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneal abrasions in the pediatric population are similar to those in adults. However, the history is typically less specific. As an example, an infant who suddenly becomes irritable with symptoms in one eye may have scratched the cornea with a fingernail. Any time a child cannot or will not open an eye, penetrating trauma must be ruled out (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Excluding penetrating trauma'",
"    </a>",
"    above); a negative history from the child or a caretaker should not be relied upon in this situation. However, most cases of penetrating trauma will involve circumstances that suggest the possibility of such an injury (eg, injury involving a projectile, broken glass, etc).",
"   </p>",
"   <p>",
"    If there is no evidence of penetrating trauma, an attempt can be made at measuring visual acuity with a technique appropriate to the age of the child (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    ). If the exam is difficult, a single drop of topical ophthalmic anesthetic may be instilled to facilitate the remainder of the exam (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Visual acuity'",
"    </a>",
"    above). The child and the caregivers should be warned that the drops will sting.",
"   </p>",
"   <p>",
"    The remainder of the examination is performed as in an adult (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Eye examination'",
"    </a>",
"    above). If a funduscopic examination is not possible an attempt should be made to at least find a red reflex.",
"   </p>",
"   <p>",
"    As discussed above, retained foreign bodies typically cause an abrasion with a characteristic appearance of multiple parallel vertical lines at the upper edge of the cornea, but the inexperienced observer may not be able to distinguish this pattern from that of any other abrasion. If the lid foreign body has been present for several hours or if time has elapsed since the instillation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    , the parallel lines may become contiguous, confounding even the experienced observer. In children, given that the history is unreliable, it is always important to inspect the lower cul-de-sac and to then flip the upper lid for direct visualization of the mucosal surface. A foreign body can be swept away with a cotton swab. Since a foreign body may be very small or light in color, it may be helpful to wipe the inner surface of the lid with a moistened swab even if no foreign body is visualized",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment in children is similar to that in adults. Antibiotic ointment is preferred over drops both for the persistent lubricating effect and because drops sting. If the child does not tolerate the visual blurring caused by ointment, the ointment can be applied at nap time or before bed.",
"   </p>",
"   <p>",
"    Children generally pull off pressure patches, which are of no proven benefit in any case, and so a pressure patch should not be attempted. Cycloplegia can improve comfort in children.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/34/24100?source=see_link\">",
"     Cyclopentolate",
"    </a>",
"    , the shortest acting of the cycloplegic agents, stings the most. For this reason, in children it may be preferable for the treating clinician to apply a single drop of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/43/35508?source=see_link\">",
"     homatropine",
"    </a>",
"    2.5 to 5 percent in the affected eye at the time of diagnosis. This will produce a sustained effect for a couple of days and thus minimize any further need for drops to be applied by the child's caregivers.",
"   </p>",
"   <p>",
"    A corneal abrasion in a child typically heals overnight as the child sleeps. Sleep can be aided with analgesia (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a sedating antihistamine.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     Codeine",
"    </a>",
"    elixir 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four to six hours can be used in young children. There may be some mucous crusting of the lids on the first morning, but if the child is happy to keep the eye open once this is wiped away, the abrasion can be considered healed.",
"   </p>",
"   <p>",
"    An infant or child with persistent discharge or unwillingness to keep the eye open during the day after the injury should be evaluated by an ophthalmologist, since these findings suggest a retained foreign body, poor healing, superinfection, or infectious keratitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/9/43153?source=see_link\">",
"       \"Patient information: Corneal abrasion (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/31/30193?source=see_link\">",
"       \"Patient information: Chemical eye injury (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment of corneal abrasions is summarized in an algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef80921 \" href=\"mobipreview.htm?37/29/38354\">",
"     algorithm 1",
"    </a>",
"    ). Most corneal abrasions heal regardless of therapy in 24 to 72 hours. Vision should return to normal in that time, although the presence of ointment on the ocular surface may reduce vision by one or two lines. Patients may be slow to heal if the diagnosis is incorrect and there is iritis or keratitis. Eye rubbing or pressing also can slow healing by interfering with epithelial migration and increasing corneal edema. Follow-up is not necessary for most small (&lt;3 mm) abrasions as long as symptoms improve and vision remains good; the exception is patients with contact lens related abrasions who require daily follow-up until the abrasion is healed to rule out infiltrate or ulcer (",
"    <a class=\"graphic graphic_picture graphicRef75303 graphicRef55332 \" href=\"mobipreview.htm?9/63/10231\">",
"     picture 3A-B",
"    </a>",
"    ). Large abrasions (&ge;3 mm), or any abrasion associated with diminished vision, require close follow-up.",
"   </p>",
"   <p>",
"    A number of points deserve further emphasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The possibility of penetrating trauma should always be considered when first assessing a patient with an abrasion and ruled out by penlight examination. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Excluding penetrating trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contact lens wearers should never wear a patch for symptom relief. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Contact lens related abrasions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No patch should be left in place for more than 24 hours. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Patching'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any patient with a corneal infiltrate, white spot, or opacity should be seen by an ophthalmologist on the day that finding is noted.",
"     </li>",
"     <li>",
"      Any patient who has a larger epithelial defect at 24 hours, who has purulent discharge, or who has experienced a drop in vision of more than 1 to 2 lines, should also be seen by an ophthalmologist.",
"     </li>",
"     <li>",
"      There are four approaches to pain control for corneal abrasion: mechanical, cycloplegic, systemic, and topical analgesia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pain control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Corneal abrasion should",
"      <strong>",
"       never",
"      </strong>",
"      be treated with topical steroid.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/1\">",
"      Chiapella AP, Rosenthal AR. One year in an eye casualty clinic. Br J Ophthalmol 1985; 69:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/2\">",
"      Knox KA, McIntee J. Nurse management of corneal abrasion. Br J Nurs 1995; 4:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/3\">",
"      Edwards RS. Ophthalmic emergencies in a district general hospital casualty department. Br J Ophthalmol 1987; 71:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/4\">",
"      Shields T, Sloane PD. A comparison of eye problems in primary care and ophthalmology practices. Fam Med 1991; 23:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/5\">",
"      Wong TY, Lincoln A, Tielsch JM, Baker SP. The epidemiology of ocular injury in a major US automobile corporation. Eye (Lond) 1998; 12 ( Pt 5):870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/6\">",
"      Alexander MM, MacLeod JD, Hall NF, Elkington AR. More than meets the eye: a study of the time lost from work by patients who incurred injuries from corneal foreign bodies. Br J Ophthalmol 1991; 75:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/7\">",
"      Peyman GA, Rahimy MH, Fernandes ML. Effects of morphine on corneal sensitivity and epithelial wound healing: implications for topical ophthalmic analgesia. Br J Ophthalmol 1994; 78:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/8\">",
"      Benson WH, Snyder IS, Granus V, et al. Tetanus prophylaxis following ocular injuries. J Emerg Med 1993; 11:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/9\">",
"      Limberg MB. A review of bacterial keratitis and bacterial conjunctivitis. Am J Ophthalmol 1991; 112:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/10\">",
"      JACKSON H. Effect of eye-pads on healing of simple corneal abrasions. Br Med J 1960; 2:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/11\">",
"      Hulbert MF. Efficacy of eyepad in corneal healing after corneal foreign body removal. Lancet 1991; 337:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/12\">",
"      Kaiser PK. A comparison of pressure patching versus no patching for corneal abrasions due to trauma or foreign body removal. Corneal Abrasion Patching Study Group. Ophthalmology 1995; 102:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/13\">",
"      Arbour JD, Brunette I, Boisjoly HM, et al. Should we patch corneal erosions? Arch Ophthalmol 1997; 115:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/14\">",
"      Flynn CA, D'Amico F, Smith G. Should we patch corneal abrasions? A meta-analysis. J Fam Pract 1998; 47:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/15\">",
"      Turner A, Rabiu M. Patching for corneal abrasion. Cochrane Database Syst Rev 2006; :CD004764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/16\">",
"      Szucs PA, Nashed AH, Allegra JR, Eskin B. Safety and efficacy of diclofenac ophthalmic solution in the treatment of corneal abrasions. Ann Emerg Med 2000; 35:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/17\">",
"      Kaiser PK, Pineda R 2nd. A study of topical nonsteroidal anti-inflammatory drops and no pressure patching in the treatment of corneal abrasions. Corneal Abrasion Patching Study Group. Ophthalmology 1997; 104:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/18\">",
"      Calder LA, Balasubramanian S, Fergusson D. Topical nonsteroidal anti-inflammatory drugs for corneal abrasions: meta-analysis of randomized trials. Acad Emerg Med 2005; 12:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/19\">",
"      Ball IM, Seabrook J, Desai N, et al. Dilute proparacaine for the management of acute corneal injuries in the emergency department. CJEM 2010; 12:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/20\">",
"      Shahinian L Jr, Jain S, Jager RD, et al. Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology 1997; 104:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/21\">",
"      Brilakis HS, Deutsch TA. Topical tetracaine with bandage soft contact lens pain control after photorefractive keratectomy. J Refract Surg 2000; 16:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/22\">",
"      DeBroff BM, Donahue SP, Caputo BJ, et al. Clinical characteristics of corneal foreign bodies and their associated culture results. CLAO J 1994; 20:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/23\">",
"      Schein OD. Contact lens abrasions and the nonophthalmologist. Am J Emerg Med 1993; 11:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34600/abstract/24\">",
"      Clemons CS, Cohen EJ, Arentsen JJ, et al. Pseudomonas ulcers following patching of corneal abrasions associated with contact lens wear. CLAO J 1987; 13:161.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6897 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-E31ECE9AB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34600=[""].join("\n");
var outline_f33_50_34600=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H436772156\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CLASSIFICATION AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Eye examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Excluding penetrating trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Visual acuity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Penlight and fundoscopic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fluorescein examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Traumatic and foreign body abrasions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Topical antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Patching",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pain control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Foreign body removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Contact lens related abrasions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Recurrent erosion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      History and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6897\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6897|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?37/29/38354\" title=\"algorithm 1\">",
"      Management corneal abrasions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6897|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/21/20816\" title=\"picture 1\">",
"      Corneal abrasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/57/11152\" title=\"picture 2\">",
"      Herpes keratitis fluorescein stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/63/36849\" title=\"picture 3A\">",
"      Corneal ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/16/44289\" title=\"picture 3B\">",
"      Corneal ulcers fluorescein",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/31/30193?source=related_link\">",
"      Patient information: Chemical eye injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/9/43153?source=related_link\">",
"      Patient information: Corneal abrasion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44486?source=related_link\">",
"      Slit lamp examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_50_34601="Etiology, clinical features, and diagnosis of minimal change disease in adults";
var content_f33_50_34601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology, clinical features, and diagnosis of minimal change disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34601/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34601/contributors\">",
"     Alain Meyrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34601/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34601/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34601/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34601/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/50/34601/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimal change disease, also called nil (Nothing-In-Light microscopy) disease, is a major cause of nephrotic syndrome in both children and adults. Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are often considered together and underlie the idiopathic nephrotic syndrome. Both are podocytopathies, which refers to glomerular diseases that are defined by primary lesions of the podocyte or glomerular epithelial cell. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H661039280\">",
"    <span class=\"h2\">",
"     Primary MCD versus primary FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There continues to be debate as to whether primary MCD and FSGS are variants of the same disease or whether they represent separate pathogenetic entities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/1\">",
"     1",
"    </a>",
"    ]. Both disorders are characterized by diffuse foot process effacement on electron microscopy, the absence of immune deposits, and a severe functional defect in glomerular permselectivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, both are responsive to glucocorticoid therapy, although the response is much more predictable in MCD than in FSGS. (See",
"    <a class=\"local\" href=\"#H58052618\">",
"     'Pathology'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\", section on 'Initial immunosuppressive therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link&amp;anchor=H445388988#H445388988\">",
"     \"Treatment of minimal change disease in adults\", section on 'Immunosuppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there is suggestive evidence that the pathogenesis of these disorders may be different in at least some patients. As described below, a glomerular permeability factor may be of primary importance in MCD. In contrast, elevated circulating soluble urokinase receptors (suPAR) levels may play a major pathogenetic role in most patients with primary FSGS, including recurrent disease after renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast to primary FSGS, serum suPAR levels appear to be normal in MCD and other causes of nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H166292499#H166292499\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Soluble urokinase receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis, etiology, causes, and diagnosis of MCD in adults will be reviewed here. The treatment of MCD as well as the pathogenesis, diagnosis, and treatment of FSGS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link\">",
"     \"Treatment of minimal change disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58052618\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glomeruli appear normal on light microscopy in patients with MCD (",
"    <a class=\"graphic graphic_picture graphicRef71232 \" href=\"mobipreview.htm?12/20/12617\">",
"     picture 1",
"    </a>",
"    ) and there are no complement or immunoglobulin deposits on immunofluorescence microscopy. Glomerular size is usually normal by standard methods of light microscopy, although enlarged glomeruli may be observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristic histologic lesion in MCD is diffuse effacement (also called \"fusion\") of the epithelial foot processes on electron microscopy (",
"    <a class=\"graphic graphic_picture graphicRef58414 \" href=\"mobipreview.htm?20/6/20584\">",
"     picture 2",
"    </a>",
"    ). More specifically, there is retraction, widening, and shortening of the foot processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The spaces between flattened podocyte foot processes are reduced in number and support the burden of plasma filtration, which may play a role in the excess albumin load into the urinary space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/7\">",
"     7",
"    </a>",
"    ]. The degree of effacement does not correlate with the degree of proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/8\">",
"     8",
"    </a>",
"    ]. Foot processes regain a normal appearance with remission of proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying cause of MCD is unclear. Accumulating evidence suggests that systemic T cell dysfunction results in the production of a glomerular permeability factor. This circulating factor directly affects the glomerular capillary wall, resulting in marked proteinuria and foot process fusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     T cell dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations are consistent with the hypothesis that cell-mediated immunity is a major pathogenetic factor in MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remission can be induced by measles, an infection known to modify cell-mediated immunity.",
"     </li>",
"     <li>",
"      The lesion of MCD occurs more frequently in patients with Hodgkin lymphoma than in the general population. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Neoplasms'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Atopic individuals are at higher risk for the development of MCD. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Allergy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , which modify cell-mediated responses, have proven benefit in the treatment of MCD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment of minimal change disease in adults\", section on 'Cyclophosphamide'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link&amp;anchor=H445388988#H445388988\">",
"       \"Treatment of minimal change disease in adults\", section on 'Immunosuppressive therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immature and relatively undifferentiated T cells (CD34+) rather than mature T cells (CD34-) have been implicated in the pathogenesis of MCD. In an animal study, for example, proteinuria and foot process effacement were observed in",
"    <span class=\"nowrap\">",
"     NOD/SCID",
"    </span>",
"    mice after the engraftment of CD34+ but not CD34- cells harvested from patients with either glucocorticoid-sensitive MCD or focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     B cell dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of B cells in the pathophysiology of MCD was for many years considered negligible. However, a number of publications on the favorable effect on MCD of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , a chimeric monoclonal antibody that depletes the B-20 cell population, suggest that a glomerular permeability factor could be produced by B cells or T cells through pathways regulated or stimulated by B cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/11\">",
"     11",
"    </a>",
"    ]. These preliminary results of MCD treatment with rituximab suggest a role for B cells in addition to T cells in the pathogenesis of MCD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of minimal change disease in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glomerular permeability factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of observations support the possibility that a circulating factor of immune origin alters glomerular permeability in MCD, thereby resulting in proteinuria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A T cell hybridoma made from a patient with MCD released a substance that, when injected into rats, induced proteinuria and foot process effacement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=see_link\">",
"       \"Mechanisms of immune injury of the glomerulus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In an in vitro assay using isolated rat glomeruli, increased permeability to albumin was noted after incubation with sera collected from a patient with MCD and Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/13\">",
"       13",
"      </a>",
"      ]. Serum permeability activity did not change in response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      but was markedly decreased by induction of remission of Hodgkin lymphoma by chemotherapy.",
"     </li>",
"     <li>",
"      Two kidneys from a patient with MCD were inadvertently transplanted into two recipients without significant baseline proteinuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/14\">",
"       14",
"      </a>",
"      ]. In both recipients, proteinuria was present at the time of grafting but diminished rapidly and was within the normal range within six weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The identity of the glomerular permeability factor in MCD has not been determined in humans. However, accruing data have implicated Th2-derived cytokines, particularly interleukin-13 (IL-13). In rats, for example, systemic overexpression of IL-13 results in albuminuria, hypoalbuminemia and, on kidney biopsy, up to 80 percent podocyte foot process fusion by electron microscopy and no significant histologic changes by light microscopy (pathologic findings similar to those in MCD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H58052618\">",
"     'Pathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Additional evidence implicating IL-13 in the pathogenesis of MCD includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T cells from patients with nephrotic syndrome spontaneously produce IL-13, while B cells express the IL-13 receptor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T cells from patients with relapsed MCD have increased expression of IL-13 compared to those from patients in remission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With cultured glomerular epithelial cells, IL-13 decreases transepithelial resistance and stimulates secretion of the proteinase, procathepsin-L [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-13 induces CD80 expression in podocytes, resulting in foot process fusion and proteinuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of the glomerular basement membrane",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which a putative circulating factor leads to a compromise of the glomerular capillary wall is incompletely understood. The glomerular capillary wall comprises three structures that separate the capillary lumen from Bowman's space: the fenestrated endothelium, the glomerular basement membrane (GBM), and the epithelium with a slit diaphragm between podocyte foot processes.",
"   </p>",
"   <p>",
"    The endothelium and the GBM are strongly anionic with the electronegative charges being provided by sialic acid and heparan sulfate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Under normal circumstances, the negative charge of the glomerular basement membrane repulses circulating albumin molecules since albumin is negatively charged at neutral pH.",
"   </p>",
"   <p>",
"    In patients with MCD, a principal theory to explain proteinuria is that the glomerular permeability factor diminishes the anionic properties of the GBM. Supporting data were derived from a series of studies in which the sieving coefficients (Bowman's space fluid-to-plasma ratio) of dextrans of various Einstein-Stokes radii and isoelectric points were determined in healthy and nephrotic humans with MCD or membranous nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/23\">",
"     23",
"    </a>",
"    ]. The sieving coefficients of anionic dextrans were less than that of neutral dextrans in normal subjects; in contrast there was no difference in sieving coefficients of anionic and neutral dextrans in patients with the nephrotic syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Role of the slit diaphragm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The slit diaphragm between podocyte foot processes plays a critical role in glomerular permeability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Defects in the slit diaphragm are visible by electron microscopy in kidneys from patients with MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of our knowledge of the proteins that make up the slit diaphragm is derived from studies of hereditary nephrotic syndromes, especially FSGS, rather than acquired proteinuric diseases, such as MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9304?source=see_link\">",
"     \"Biology of glomerular podocytes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H661039477\">",
"    <span class=\"h2\">",
"     Genetic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic defects may underlie rare familial forms of MCD that occur in inbred kindreds. In one study, linkage to NPHS2, the gene responsible for an autosomal recessive form of focal segmental glomerulosclerosis, was examined in a cohort of 32 children from 12 families with familial steroid-sensitive idiopathic nephrotic syndrome; MCD was present in all 12 children who underwent renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/28\">",
"     28",
"    </a>",
"    ]. Linkage studies and mutational analysis",
"    <strong>",
"     excluded",
"    </strong>",
"    NPHS2 involvement, suggesting the existence of a distinct gene locus for this disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H27#H27\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'NPHS2 gene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of MCD are idiopathic (or primary) and not clearly associated with an underlying disease or event. With secondary MCD, the onset of nephrotic syndrome occurs concurrently or following an extraglomerular or glomerular disease process.",
"   </p>",
"   <p>",
"    MCD is associated with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drugs",
"     </li>",
"     <li>",
"      Neoplasms",
"     </li>",
"     <li>",
"      Infections",
"     </li>",
"     <li>",
"      Allergy",
"     </li>",
"     <li>",
"      Other glomerular diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many drugs can induce a nephrotic syndrome with the histopathologic appearance of MCD. These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors. NSAIDs are the most common cause of secondary MCD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=see_link&amp;anchor=H3#H3\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\", section on 'Acute interstitial nephritis and nephrotic syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antimicrobial drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      , rifampicin, cephalosporins)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/32999?source=see_link&amp;anchor=H5#H5\">",
"       \"Renal toxicity of lithium\", section on 'Nephrotic syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      D-penicillamine and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/12/21699?source=see_link\">",
"       tiopronin",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/11/23737?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of Wilson disease\", section on 'Adverse effects and their management'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       Pamidronate",
"      </a>",
"      and other bisphosphates (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link&amp;anchor=H2#H2\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Proteinuria and renal insufficiency'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      and 5-aminosalicylic acid derivatives",
"     </li>",
"     <li>",
"      Trimethadione",
"     </li>",
"     <li>",
"      Immunizations",
"     </li>",
"     <li>",
"      Gamma interferon",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;MCD has been associated with malignancies, particularly hematologic malignancies, such as Hodgkin lymphoma (previously called Hodgkin disease), non-Hodgkin lymphoma, and leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. In a review of two large series of patients with Hodgkin lymphoma, 0.4 percent had MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many cases, the underlying hematologic disease is already apparent at the time of onset of the nephrotic syndrome. The degree of proteinuria usually parallels that of the malignancy, with the proteinuria disappearing when remission of the malignancy is obtained with radiotherapy and chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/33,34,36\">",
"     33,34,36",
"    </a>",
"    ]. However, there are patients in whom the course of MCD does not correlate with the course of the lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients, MCD precedes the discovery of the lymphoma by several months or even years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. In a review of 21 patients who had both MCD and Hodgkin lymphoma, eight (38 percent) were diagnosed with MCD a median of two years",
"    <strong>",
"     prior",
"    </strong>",
"    to the diagnosis of malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/34\">",
"     34",
"    </a>",
"    ]. Among these eight patients, one was steroid-dependent and four were steroid-resistant, but all entered remission when the lymphoma was successfully treated.",
"   </p>",
"   <p>",
"    Solid tumors are more commonly associated with an immune complex-mediated disease such as membranous nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/37\">",
"     37",
"    </a>",
"    ]. However, rare cases of MCD associated with solid tumors have been reported. These include thymoma, renal cell carcinoma, mesothelioma, and bronchogenic, colon, bladder, lung, breast, pancreatic, duodenal, and prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/30,38\">",
"     30,38",
"    </a>",
"    ]. In some, but not all, reported cases, ablation of the tumor was followed by remission of the nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4744?source=see_link&amp;anchor=H11884692#H11884692\">",
"     \"Overview of renal disease associated with malignancy\", section on 'Glomerular diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;MCD has rarely been associated with infections including syphilis, tuberculosis, mycoplasma, ehrlichiosis, hepatitis C virus, and Echinococcus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. HIV infection is most often associated with a collapsing focal segmental glomerulosclerosis but minimal change disease has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4168?source=see_link\">",
"     \"Overview of kidney disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of allergy has been described in up to 30 percent of cases of MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/1,40\">",
"     1,40",
"    </a>",
"    ]. Multiple allergens have been reported in association with MCD, including fungi, poison ivy, ragweed and timothy grass pollen, house dust, medusa stings, bee stings, and cat fur. The onset or occurrence of relapses of nephrotic syndrome can be triggered by an allergic reaction or bee sting.",
"   </p>",
"   <p>",
"    Limited evidence suggests that relapsing MCD may be due to food allergy in some patients. In a small series, an oligoantigenic diet induced remission in some patients with steroid-resistant MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/41\">",
"     41",
"    </a>",
"    ]. This finding needs to be replicated in other studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other glomerular diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;MCD may be associated with mesangial IgA deposits and mild mesangial proliferation suggesting the concurrence of IgA nephropathy and MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/39,42-44\">",
"     39,42-44",
"    </a>",
"    ]. The mechanism underlying this relationship is not understood and may reflect concurrent disease, especially in Asians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. These patients respond to glucocorticoid therapy with remission of the nephrotic syndrome but relapses can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/39,42-44\">",
"     39,42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the relationship is unclear, there are reports of MCD occurring in association with the following glomerular or renal diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/30,45\">",
"     30,45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic lupus erythematosus",
"     </li>",
"     <li>",
"      Type 1 diabetes",
"     </li>",
"     <li>",
"      Polycystic kidney disease",
"     </li>",
"     <li>",
"      HIV nephropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other, mostly autoimmune, conditions have been described in association with MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/30\">",
"     30",
"    </a>",
"    ]. The mechanisms underlying this association are not identified, and the association may be coincidental rather than causal. These include chronic graft-versus-host-disease after peripheral blood stem cell transplantation, sclerosing cholangitis, sarcoidosis, Graves' disease, thyroiditis, vasculitis, myasthenia gravis, Guillain-Barr&eacute; syndrome, dermatitis herpetiformis, primary biliary cirrhosis, antiphospholipid syndrome and stiff-person syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/30,46-49\">",
"     30,46-49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58052441\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;MCD is the most common cause of nephrotic syndrome in children, with variations in incidence based upon age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among children under age 10 who present with idiopathic nephrotic syndrome, MCD is the underlying disease in about 90 percent.",
"     </li>",
"     <li>",
"      Among children over age 10, MCD accounts for only 50 percent of cases with an increased percentage of FSGS in this age group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Idiopathic nephrotic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MCD accounts for a smaller proportion of cases of nephrotic syndrome in adults. In a study published in 1987, MCD was present in 10 to 15 percent of cases of adult nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/51\">",
"     51",
"    </a>",
"    ]. The percentage of nephrotic adults with MCD has decreased in more recent years, in contrast to an increased incidence of focal segmental glomerulosclerosis (FSGS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/52-55\">",
"     52-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to age, ethnicity is an important predictor of the percentage of nephrotic patients with MCD, although epidemiologic studies may be confounded by prevailing ethnic differences in the studied populations. The percentage of nephrotic patients with MCD is highest in Asian and Caucasian populations, while the percentage of nephrotic patients with underlying FSGS is highest in African-American populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H9804961#H9804961\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'FSGS in African Americans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;MCD is in most patients characterized by the sudden onset over days to a week or two of the signs and symptoms of the nephrotic syndrome, often following an upper respiratory or systemic infection. The nephrotic syndrome is characterized by the constellation of proteinuria, mostly albuminuria, (almost always greater than 3.5 to 4.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and occasionally more than 15 to 20",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    weight gain and then edema, and, on laboratory testing, hypoalbuminemia (serum albumin that may be less than 1.5 to 2.0",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    and in most cases hyperlipidemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best data on the rate of onset of disease manifestations come from patients with MCD in remission following glucocorticoid therapy who are monitoring urinary protein excretion with a dipstick, initially at one to two week intervals or at the first sign of &ldquo;frothy&rdquo; urine. A positive dipstick test (usually 1+ or greater) is repeated the next day and, if at or above this level, the physician should be contacted. Rapid weight gain followed by detectable edema occurs soon thereafter unless therapy is initiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of minimal change disease in adults\", section on 'Treatment of relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typically sudden onset of nephrotic syndrome in MCD is in contrast to the gradual increase in proteinuria over weeks to months in most other causes of nephrotic syndrome such as membranous nephropathy and most variants of focal segmental glomerulosclerosis (FSGS), with the exception of the glomerular tip variant. The sudden onset of nephrotic syndrome is reasonably specific but not very sensitive for MCD in adults and should",
"    <strong>",
"     not",
"    </strong>",
"    be used to avoid performing a renal biopsy to confirm the diagnosis. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Tip variant'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H23#H23\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the role of renal biopsy in adults, a presumptive diagnosis of MCD can be made and appropriate therapy initiated without renal biopsy in young children who fulfill certain criteria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=see_link&amp;anchor=H20#H20\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Initial therapy versus renal biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other renal manifestations that may be seen in patients with MCD include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microscopic hematuria is common in adults with MCD and occurs in 20 to 25 percent of children, but is not associated with a difference in clinical course [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/1,50,57\">",
"       1,50,57",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=see_link&amp;anchor=H14#H14\">",
"       \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Urinalysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The serum creatinine concentration may be modestly (30 to 40 percent) elevated at presentation in both adults and children. Acute renal failure has been is an infrequent complication that has been primarily described in adults. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Acute renal failure'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18598?source=see_link\">",
"       \"Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=see_link&amp;anchor=H18#H18\">",
"       \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Estimation of GFR'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical findings at presentation in adults with MCD were illustrated in a retrospective analysis of 95 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/57\">",
"     57",
"    </a>",
"    ]. The following findings were noted; the age and laboratory results represent mean values:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &mdash; 45 years",
"     </li>",
"     <li>",
"      Serum creatinine &mdash; 1.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (124",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Estimated glomerular filtration rate &mdash; 72",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      Proteinuria &mdash; 9.9",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"     </li>",
"     <li>",
"      Hematuria &mdash; 29 percent",
"     </li>",
"     <li>",
"      Serum albumin &mdash; 2.2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Serum cholesterol &mdash; 421",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (10.9",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Hypertension &mdash; 43 percent",
"     </li>",
"     <li>",
"      Acute renal failure &mdash; 18 percent (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Acute renal failure'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530830689\">",
"    <span class=\"h2\">",
"     Complications of nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above findings, the nephrotic syndrome can be associated with the following complications, the pathogenesis and manifestations of which are discussed in detail elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased risk of thromboembolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"       \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25974?source=see_link&amp;anchor=H5#H5\">",
"       \"Complications of idiopathic nephrotic syndrome in children\", section on 'Thromboembolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased susceptibility to infection, particularly with encapsulated organisms, which is best described in children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Infection'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25974?source=see_link&amp;anchor=H3#H3\">",
"       \"Complications of idiopathic nephrotic syndrome in children\", section on 'Bacterial infection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, a presumptive diagnosis of MCD is usually made based upon the clinical findings at presentation and the high prevalence of MCD as a cause of the nephrotic syndrome, particularly in children under the age of 10. Almost all children with MCD respond to a short course of glucocorticoids. Childhood nephrosis is considered steroid-resistant (SR-NS) when no remission is achieved after about two months of full-dose steroid therapy. Pediatricians usually restrict renal biopsy to individuals with SR-NS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Idiopathic nephrotic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, adults with MCD present with clinical features that are consistent with other glomerular diseases and may not respond to a short course of glucocorticoids. Some adults remit within eight weeks, while others require up to 16 weeks of glucocorticoid therapy (",
"    <a class=\"graphic graphic_figure graphicRef58623 \" href=\"mobipreview.htm?41/47/42751\">",
"     figure 1",
"    </a>",
"    ), with the associated hazards of steroid toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34601/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of minimal change disease in adults\", section on 'Time course and patient age'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H668779289\">",
"    <span class=\"h2\">",
"     Distinction from other causes of nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the diagnosis of MCD (versus other causes of the nephrotic syndrome) cannot be predictably made from the clinical presentation, a renal biopsy is almost always performed in adults who present with the nephrotic syndrome to both establish the diagnosis and guide therapy. As mentioned above, MCD is characterized pathologically by normal appearing glomeruli on light microscopy (",
"    <a class=\"graphic graphic_picture graphicRef71232 \" href=\"mobipreview.htm?12/20/12617\">",
"     picture 1",
"    </a>",
"    ) and the absence of complement or immunoglobulin deposits on immunofluorescence microscopy. The characteristic histologic lesion is diffuse effacement of the epithelial foot processes on electron microscopy (",
"    <a class=\"graphic graphic_picture graphicRef58414 \" href=\"mobipreview.htm?20/6/20584\">",
"     picture 2",
"    </a>",
"    ). Although foot process effacement is also seen in other causes of the nephrotic syndrome (eg, FSGS [including HIV-associated FSGS], membranous nephropathy [including membranous lupus], diabetic nephropathy, and, amyloidosis), these disorders have characteristic findings on light and immunofluorescence microscopy and, in some disorders, blood test abnormalities that are not seen in MCD. (See",
"    <a class=\"local\" href=\"#H58052618\">",
"     'Pathology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link&amp;anchor=H93802546#H93802546\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Nephrotic syndrome without a nephritic sediment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to MCD, there are three other disorders that usually present with the nephrotic syndrome and that may show only minor changes on light microscopy: idiopathic mesangial proliferative glomerulonephritis; IgM nephropathy; and C1q nephropathy. These disorders may represent variants of minimal change disease or FSGS but some clinicians believe that they are often separate conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41717?source=see_link\">",
"     \"Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H668779297\">",
"    <span class=\"h3\">",
"     MCD versus FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With primary focal segmental glomerulosclerosis (FSGS), the biopsy diagnosis requires the finding of segmental glomerulosclerosis in at least one glomerulus in addition to diffuse foot process effacement. However, sclerotic lesions are focal and affected glomeruli may be missed, leading to an incorrect diagnosis of MCD. As an example, sclerotic changes occur first in the juxtamedullary glomeruli, which may not be present in superficial biopsies that contain only the outer cortex or in biopsies that contain fewer than eight glomeruli where sampling error may be important. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Classic FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary FSGS can result from an adaptive response to glomerular hypertrophy or hyperfiltration resulting from nephron loss (as in reflux nephropathy), podocyte injury via a different mechanism from that seen in primary FSGS, renal vasodilation as seen in massive obesity and other settings, or healing of prior inflammatory injury due to disorders such as IgA nephropathy, focal lupus nephritis, or small vessel vasculitis. Affected patients typically have subnephrotic proteinuria, a normal or near normal serum albumin concentration, no peripheral edema, focal rather than diffuse foot process effacement, and a normal or reduced estimated glomerular filtration rate. Establishing the correct diagnosis is important since these patients are",
"    <strong>",
"     not",
"    </strong>",
"    treated with immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Secondary FSGS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H1498484543#H1498484543\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Distinguishing between primary and secondary FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H668779351\">",
"    <span class=\"h2\">",
"     MCD in the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients with MCD present with the nephrotic syndrome as do younger patients. However, the histologic diagnosis of MCD may be more difficult in older patients. The aging kidney commonly shows obsolescent glomeruli along with vascular lesions and interstitial fibrosis. These findings may suggest primary FSGS or MCD superimposed upon changes associated with aging. Standard light, immunofluorescence, and electron microscopy may not easily distinguish between these disorders.",
"   </p>",
"   <p>",
"    However, the following features may allow the clinician to distinguish MCD from primary FSGS in elderly patients with superimposed arteriolo- and arterio-nephrosclerosis using morphologic criteria alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The glomerulosclerosis that accompanies aging is more often focal and global rather than focal and segmental as is observed in primary or secondary FSGS.",
"     </li>",
"     <li>",
"      Extensive \"collapsing\" or \"tip\" lesions suggest a primary form of FSGS rather than MCD, since these lesions are not the consequence of the aging process in the kidneys.",
"     </li>",
"     <li>",
"      Extensive focal and segmental IgM deposits support the diagnosis of FSGS rather than MCD, but these are seldom present in the absence of typical focal and segmental lesions on light microscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elderly patients for whom a definitive diagnosis of MCD cannot be made because of concurrent lesions of aging sometimes undergo a trial of treatment with glucocorticoids. Remission is induced within two to four months of appropriate dose glucocorticoid therapy in approximately 75 to 90 percent of patients with MCD (",
"    <a class=\"graphic graphic_figure graphicRef58623 \" href=\"mobipreview.htm?41/47/42751\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of minimal change disease in adults\", section on 'Glucocorticoid-resistant MCD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, adults with nephrotic syndrome due to MCD may present with acute renal failure (see",
"    <a class=\"local\" href=\"#H18\">",
"     'General presentation'",
"    </a>",
"    above). The combination of nephrotic syndrome and acute renal failure can also occur in a limited number of other settings including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Collapsing focal segmental glomerulosclerosis, either idiopathic or associated with HIV infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=see_link\">",
"       \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=see_link\">",
"       \"HIV-associated nephropathy (HIVAN)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Crescentic glomerulonephritis superimposed upon membranous nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H22#H22\">",
"       \"Causes and diagnosis of membranous nephropathy\", section on 'Crescentic glomerulonephritis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephrotic syndrome secondary to monoclonal immunoglobulin deposition disease may also develop myeloma cast nephropathy and acute renal failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27400?source=see_link\">",
"       \"Types of renal disease in multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal vein thrombosis is an occasional complication of the nephrotic syndrome. The renal vein thrombosis is usually chronic and does",
"    <strong>",
"     not",
"    </strong>",
"    result in acute renal failure since thrombosis of a main renal vein is followed by the development of a rich collateral circulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link&amp;anchor=H8#H8\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minimal change disease (MCD) is a major cause of nephrotic syndrome in both children and adults and, together with focal segmental glomerulosclerosis (FSGS), underlies the idiopathic nephrotic syndrome. MCD and FSGS may be variants of the same disease or represent separate pathophysiologic entities. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the pathogenesis is unclear, systemic T cell dysfunction appears to produce increasing levels of a glomerular permeability factor in MCD. This circulating factor directly affects the glomerular capillary wall, resulting in foot process fusion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histologically, MCD is characterized by normal appearing glomeruli by light microscopy and the absence of complement or immunoglobulin deposits by immunofluorescence microscopy. The characteristic histologic lesion in MCD is diffuse effacement of the podocyte foot processes on electron microscopy. (See",
"      <a class=\"local\" href=\"#H58052618\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MCD may be primary or secondary to drugs, neoplasm, or infection, and is often associated with allergy. MCD occurs in adults of all ages and is the cause of 10 to 15 percent of all cases of adult nephrotic syndrome (in children the number is 90 to 95 percent of all cases of nephrotic syndrome). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H58052441\">",
"       'Incidence'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      MCD is characterized by the sudden onset of the signs and symptoms of the nephrotic syndrome. Microscopic hematuria is common in adults with MCD and acute kidney injury may also occur. Unlike children, a kidney biopsy is necessary in adults to diagnose MCD. The diagnosis is based upon the characteristic findings on electron microscopy and the exclusion of histologic features that characterize other disorders with foot process effacement. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of MCD in adults includes disorders that also may present with the acute onset of the nephrotic syndrome, such as the glomerular tip lesion variant of FSGS, are characterized by the combination of the nephrotic syndrome and acute kidney injury, or have foot process effacement on renal biopsy. (See",
"      <a class=\"local\" href=\"#H668779289\">",
"       'Distinction from other causes of nephrotic syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Meyrier, A, Niaudet P. Minimal changes and focal-segmental glomerulosclerosis.In: Oxford Textbook of Clinical Nephrology, vol. 1, 3rd edition, Davison, AM, Cameron, JS, Gr&uuml;nfeld, E, et al. (Eds), Oxford University Press, Oxford 2005. p. 439.",
"    </li>",
"    <li>",
"     Mason, PD. Minimal change disease and primary focal segmental glomerulosclerosis. In: Comprehensive Clinical Nephrology, 2nd ed, Johnson, RJ &amp; Feehally, J (ed), Elsevier, Philadelphia 2000. p 271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/3\">",
"      Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/4\">",
"      Fogo A, Hawkins EP, Berry PL, et al. Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int 1990; 38:115.",
"     </a>",
"    </li>",
"    <li>",
"     Schnaper, HW, Robson, AA, Kopp, JB. Nephrotic syndrome: minimal change nephropathy, focal segmental glomerulosclerosis, and collapsing glomerulopathy. In: Diseases of the Kidney and Urinary Tract, 8th ed, Schrier, RW (ed), Lippincott Williams &amp; Wlikins, Philadelphia 2007. p1585.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/6\">",
"      Shirato I. Podocyte process effacement in vivo. Microsc Res Tech 2002; 57:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/7\">",
"      Smithies O. Why the kidney glomerulus does not clog: a gel permeation/diffusion hypothesis of renal function. Proc Natl Acad Sci U S A 2003; 100:4108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/8\">",
"      van den Berg JG, van den Bergh Weerman MA, Assmann KJ, et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004; 66:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/9\">",
"      Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974; 2:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/10\">",
"      Sellier-Leclerc AL, Duval A, Riveron S, et al. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol 2007; 18:2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/11\">",
"      Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant 2008; 23:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/12\">",
"      Koyama A, Fujisaki M, Kobayashi M, et al. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991; 40:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/13\">",
"      Aggarwal N, Batwara R, McCarthy ET, et al. Serum permeability activity in steroid-resistant minimal change nephrotic syndrome is abolished by treatment of Hodgkin disease. Am J Kidney Dis 2007; 50:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/14\">",
"      Ali AA, Wilson E, Moorhead JF, et al. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation 1994; 58:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/15\">",
"      Lai KW, Wei CL, Tan LK, et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 2007; 18:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/16\">",
"      Kimata H, Fujimoto M, Furusho K. Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome. Eur J Immunol 1995; 25:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/17\">",
"      Yap HK, Cheung W, Murugasu B, et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 1999; 10:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/18\">",
"      Cheung W, Wei CL, Seah CC, et al. Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome. Pediatr Nephrol 2004; 19:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/19\">",
"      Van Den Berg JG, Aten J, Chand MA, et al. Interleukin-4 and interleukin-13 act on glomerular visceral epithelial cells. J Am Soc Nephrol 2000; 11:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/20\">",
"      Van Den Berg JG, Aten J, Annink C, et al. Interleukin-4 and -13 promote basolateral secretion of H(+) and cathepsin L by glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 282:F26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/21\">",
"      Ishimoto T, Shimada M, Araya CE, et al. Minimal change disease: a CD80 podocytopathy? Semin Nephrol 2011; 31:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/22\">",
"      Carrie BJ, Salyer WR, Myers BD. Minimal change nephropathy: an electrochemical disorder of the glomerular membrane. Am J Med 1981; 70:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/23\">",
"      Guasch A, Deen WM, Myers BD. Charge selectivity of the glomerular filtration barrier in healthy and nephrotic humans. J Clin Invest 1993; 92:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/24\">",
"      Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001; 108:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/25\">",
"      Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol 2005; 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/26\">",
"      Patrakka J, Lahdenkari AT, Koskimies O, et al. The number of podocyte slit diaphragms is decreased in minimal change nephrotic syndrome. Pediatr Res 2002; 52:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/27\">",
"      Chiang CK, Inagi R. Glomerular diseases: genetic causes and future therapeutics. Nat Rev Nephrol 2010; 6:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/28\">",
"      Fuchshuber A, Gribouval O, Ronner V, et al. Clinical and genetic evaluation of familial steroid-responsive nephrotic syndrome in childhood. J Am Soc Nephrol 2001; 12:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/29\">",
"      Almansori M, Kovithavongs T, Qarni MU. Cyclooxygenase-2 inhibitor-associated minimal-change disease. Clin Nephrol 2005; 63:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/30\">",
"      Glassock RJ. Secondary minimal change disease. Nephrol Dial Transplant 2003; 18 Suppl 6:vi52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/31\">",
"      Lecoules S, Duvic C, H&eacute;rody M, N&eacute;d&eacute;lec G. [Tiopronin-induced nephrotic syndrome with minimal glomerular lesions]. Presse Med 1999; 28:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/32\">",
"      Aoyama M, Sugimoto T, Yokono T, et al. Minimal-change nephropathy and chronic hepatitis C infection: coincidental or associated? Nephrol Dial Transplant 2007; 22:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/33\">",
"      Dabbs DJ, Striker LM, Mignon F, Striker G. Glomerular lesions in lymphomas and leukemias. Am J Med 1986; 80:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/34\">",
"      Audard V, Larousserie F, Grimbert P, et al. Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature. Kidney Int 2006; 69:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/35\">",
"      Korzets Z, Golan E, Manor Y, et al. Spontaneously remitting minimal change nephropathy preceding a relapse of Hodgkin's disease by 19 months. Clin Nephrol 1992; 38:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/36\">",
"      Alpers CE, Cotran RS. Neoplasia and glomerular injury. Kidney Int 1986; 30:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/37\">",
"      Meyrier A, Delahousse M, Callard P, Rainfray M. Minimal change nephrotic syndrome revealing solid tumors. Nephron 1992; 61:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/38\">",
"      Auguet T, Lorenzo A, Colomer E, et al. Recovery of minimal change nephrotic syndrome and acute renal failure in a patient withRenal cell carcinoma. Am J Nephrol 1998; 18:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/39\">",
"      Boix E, Rivera F, Gil CM, et al. Steroid-responsive nephrotic syndrome with minimal-change disease and IgA deposits in a HIV-infected patient. Nephrol Dial Transplant 2000; 15:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/40\">",
"      Abdel-Hafez M, Shimada M, Lee PY, et al. Idiopathic nephrotic syndrome and atopy: is there a common link? Am J Kidney Dis 2009; 54:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/41\">",
"      Lagrue G, Laurent J, Rostoker G. Food allergy and idiopathic nephrotic syndrome. Kidney Int Suppl 1989; 27:S147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/42\">",
"      Lai KN, Lai FM, Chan KW, et al. An overlapping syndrome of IgA nephropathy and lipoid nephrosis. Am J Clin Pathol 1986; 86:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/43\">",
"      Cheng IK, Chan KW, Chan MK. Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission. Am J Kidney Dis 1989; 14:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/44\">",
"      Westhoff TH, Waldherr R, Loddenkemper C, et al. Mesangial IgA deposition in minimal change nephrotic syndrome: coincidence of different entities or variant of minimal change disease? Clin Nephrol 2006; 65:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/45\">",
"      Dube GK, Markowitz GS, Radhakrishnan J, et al. Minimal change disease in systemic lupus erythematosus. Clin Nephrol 2002; 57:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/46\">",
"      Rao PS. Nephrotic syndrome in patients with peripheral blood stem cell transplant. Am J Kidney Dis 2005; 45:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/47\">",
"      Lai TS, Lin WC, Wu MS, et al. Primary biliary cirrhosis associated with minimal change disease. Nephrol Dial Transplant 2007; 22:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/48\">",
"      Rossi&ntilde;ol T, Cervera R, L&oacute;pez C, et al. Antiphospholipid syndrome and minimal change nephropathy. Lupus 2006; 15:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/49\">",
"      Erg&uuml;n I, Akbostanci MC, Canbakan B, et al. Minimal change nephrotic syndrome with stiff-person syndrome: is there a link? Am J Kidney Dis 2005; 46:e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/50\">",
"      Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/51\">",
"      Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis 1987; 10:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/52\">",
"      Filler G, Young E, Geier P, et al. Is there really an increase in non-minimal change nephrotic syndrome in children? Am J Kidney Dis 2003; 42:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/53\">",
"      Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997; 30:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/54\">",
"      Bonilla-Felix M, Parra C, Dajani T, et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int 1999; 55:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/55\">",
"      Srivastava T, Simon SD, Alon US. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 1999; 13:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/56\">",
"      Feehally J, Kendell NP, Swift PG, Walls J. High incidence of minimal change nephrotic syndrome in Asians. Arch Dis Child 1985; 60:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/57\">",
"      Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007; 2:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34601/abstract/58\">",
"      Nakayama M, Katafuchi R, Yanase T, et al. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002; 39:503.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3046 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34601=[""].join("\n");
var outline_f33_50_34601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H661039280\">",
"      Primary MCD versus primary FSGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58052618\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      T cell dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      B cell dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glomerular permeability factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of the glomerular basement membrane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Role of the slit diaphragm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H661039477\">",
"      Genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other glomerular diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58052441\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H530830689\">",
"      Complications of nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H668779289\">",
"      Distinction from other causes of nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H668779297\">",
"      - MCD versus FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H668779351\">",
"      MCD in the elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3046\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3046|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/47/42751\" title=\"figure 1\">",
"      Response to steroids in MCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3046|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/20/12617\" title=\"picture 1\">",
"      Light microscopy in minimal change disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/6/20584\" title=\"picture 2\">",
"      Electron microscopy in minimal change disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18598?source=related_link\">",
"      Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9304?source=related_link\">",
"      Biology of glomerular podocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25974?source=related_link\">",
"      Complications of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=related_link\">",
"      HIV-associated nephropathy (HIVAN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=related_link\">",
"      Mechanisms of immune injury of the glomerulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41717?source=related_link\">",
"      Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4168?source=related_link\">",
"      Overview of kidney disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4744?source=related_link\">",
"      Overview of renal disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/11/23737?source=related_link\">",
"      Treatment of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=related_link\">",
"      Treatment of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_50_34602="Head and neck sarcomas";
var content_f33_50_34602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Head and neck sarcomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34602/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34602/contributors\">",
"     Steven J Charous, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34602/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34602/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34602/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34602/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34602/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34602/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34602/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/50/34602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/50/34602/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/50/34602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck sarcomas are relatively rare tumors, and this makes rigorous study of clinical behavior difficult. As a result, treatment algorithms are drawn from retrospective case series and principles are derived from treatment of sarcomas at other sites, rather than from large clinical trials. Their study is also made more difficult by the diversity of histological subtypes and the variable clinical behavior. Furthermore, the confining anatomy and proximity to vital structures makes even adherence to traditional margin-driven therapy challenging.",
"   </p>",
"   <p>",
"    The demographics of head and neck sarcomas, the clinical behavior of the common subtypes, and general treatment principles will be reviewed here. An overview of the epidemiology, clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue and bone sarcomas, and a discussion of treatment for sarcomas arising at other sites are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link\">",
"       \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=see_link\">",
"       \"Chondrosarcoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link\">",
"       \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18327?source=see_link\">",
"       \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=see_link\">",
"       \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=see_link\">",
"       \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=see_link\">",
"       \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=see_link\">",
"       \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=see_link\">",
"       \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY, HISTOLOGIC DISTRIBUTION, AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcomas of the head and neck account for about 2 percent of all head and neck malignancies and 4 to 10 percent of all sarcomas in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The 1000 to 1500 cases of head and neck sarcoma diagnosed each year in the United States are comprised of about 10 main histologic subtypes and many minor subtypes. The main histologic subtypes are rhabdomyosarcoma (RMS) in children, osteosarcoma (and chondrosarcoma), angiosarcoma, the common adult soft-tissue sarcomas (malignant fibrous histiocytoma [MFH], now referred to as pleomorphic undifferentiated sarcomas, liposarcoma, fibrosarcoma, leiomyosarcoma [LMS], synovial sarcoma), and malignant peripheral nerve sheath tumors (MPNST). In series in which desmoid tumors (aggressive fibromatosis) and dermatofibrosarcoma protuberans (DFSP) are included, these tumors account for a large proportion of cases. Other less commonly occurring sarcomas include hemangiopericytoma, Ewing sarcoma, and alveolar soft parts sarcoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link&amp;anchor=H18#H18\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Histologic classification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227072#H12227072\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Histopathology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical and histologic makeup of any of the large series of head and neck sarcomas is highly dependent upon the nature of the reporting institution or the clinical practice of the reporting physician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/4-14\">",
"     4-14",
"    </a>",
"    ]. General oncologic surgeons are likely to see a different array of patients compared to otolaryngologic surgeons, pediatric surgeons, or plastic surgeons. Many series exclude bone sarcomas or benign or low malignant potential tumors (eg, desmoid tumors and DFSP). Some series include pediatric sarcomas and thus have a very large proportion of RMS; others exclude these subtypes. Many of the largest series use older pathologic classification schemes in which tumors of the fibrosarcoma spectrum were not yet re-categorized appropriately as MFH or pleomorphic sarcoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227072#H12227072\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Histopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these variations and limitations in reporting, some generalizations can be made about the demographics of head and neck sarcomas and the histologic and anatomic makeup of these tumors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 30 percent of head and neck sarcomas occur in children, with the majority of these being RMS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The median age at diagnosis for all head and neck sarcomas is 35 to 40 years, when children are included, and 45 years when they are not.",
"     </li>",
"     <li>",
"      Different subtypes affect different age groups. As examples, RMS occurs predominantly in children (median age of about six years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/15\">",
"       15",
"      </a>",
"      ]) while angiosarcomas most often arise in the elderly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most series report a slight male predominance.",
"     </li>",
"     <li>",
"      Any site within the head or neck can be a primary site for a sarcoma, since connective tissue is ubiquitous. Primary site predominance is determined by histologic subtype and is discussed within the following sections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15527574\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary radiation-related head and neck sarcomas are well described and account for several percent of head and neck sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/6,7,16,17\">",
"     6,7,16,17",
"    </a>",
"    ]. Other pathogenetic factors are similar to those for other soft tissue sarcomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=see_link\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H24\">",
"     'Angiosarcoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients generally present with a palpable mass (especially in the neck), skin changes (especially on the scalp or face), or subsite-specific symptoms (eg, hoarseness with laryngeal primaries, dysphagia with oropharyngeal tumors, epistaxis, nasal obstruction, or cranial nerve deficits with skull base tumors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/1,10,14,18\">",
"     1,10,14,18",
"    </a>",
"    ]. Specific presenting symptoms will be discussed according to histologic subtype below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15528177\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all patients with a suspected head and neck neoplasm, a complete examination of the head and neck, with particular attention to the cranial nerves, is essential. For most patients, magnetic resonance imaging (MRI) is the superior neuroimaging study. In many cases, CT scanning complements MRI and both are helpful in surgical planning, particularly for bone sarcomas.&nbsp;Models can now be made preoperatively from CT scans for expected bone defects, allowing reconstructive planning and preparation to begin preoperatively, thus increasing the efficiency of the intraoperative repair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=see_link&amp;anchor=H2#H2\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\", section on 'Preoperative evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pretreatment evaluation should also include a directed metastatic workup, with a CT of the chest, a complete blood count, and assessment of serum alkaline phosphatase. A more extensive diagnostic workup (eg, CT of the brain, radionuclide bone scan, PET scan) should generally be based upon symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical suspicion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227142#H12227142\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Radiographic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of PET scanning and integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging in the staging workup for soft tissue sarcomas (including rhabdomyosarcomas) and bone sarcomas, including those arising in the head and neck, is not clearly defined. There is no consensus on the appropriate use of this imaging modality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18327?source=see_link&amp;anchor=H14#H14\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\", section on 'Metastatic workup'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227163#H12227163\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'PET and PET/CT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines from the NCCN suggest a PET",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone scan in the diagnostic workup of a suspected osteosarcoma but not soft tissue sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/19\">",
"     19",
"    </a>",
"    ]. Imaging guidelines from the Children&rsquo;s Oncology Group Bone Tumor Committee recommend radionuclide bone scan",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PET scan for whole body staging for all patients with osteosarcoma (",
"    <a class=\"graphic graphic_table graphicRef55623 \" href=\"mobipreview.htm?17/11/17597\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/20\">",
"     20",
"    </a>",
"    ]. Regardless of which is chosen, the same imaging modality should be used throughout treatment and during posttreatment surveillance. Ideally, a PET scan or bone scan should be performed prior to biopsy to avoid a biopsy-related false positive result. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link&amp;anchor=H14#H14\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Staging work-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Performing a biopsy to obtain representative tissue for histologic evaluation is an important component of the initial evaluation. However, the biopsy method can affect subsequent treatment and thus should be carefully planned in conjunction with the surgeon who will perform the definitive surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227177#H12227177\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15528479\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM staging system for head and neck cancers is not applicable to non-epithelial tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\", section on 'TNM staging system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Head and neck sarcomas are staged using the same classification for sarcomas arising at other body sites. The staging schema used for soft tissue sarcomas, rhabdomyosarcomas, and for primary bone sarcomas (both osteosarcomas and chondrosarcomas) are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18327?source=see_link&amp;anchor=H17#H17\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\", section on 'Staging and prognostic stratification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link&amp;anchor=H17#H17\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Staging system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15528150\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY, AND PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the natural history of head and neck sarcomas parallels that of their non-head and neck counterparts, but with a higher rate of local recurrence after treatment and lower overall survival rates. The worse outcomes with head and neck primary sarcomas can be illustrated by a single institution series comparing outcomes among 102 patients with head and neck sarcoma and 1044 patients with extremity or superficial trunk lesions, all of whom were treated between 1960 and 1999 with surgery and radiation therapy (RT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/22\">",
"     22",
"    </a>",
"    ]. At five years, local control rates were inferior for patients with head and neck primaries (74 versus 85 percent) as was disease-specific survival (64 versus 76 percent).",
"   </p>",
"   <p>",
"    It is not clear that a primary site in the head and neck constitutes an independent risk factor for a worse prognosis per se. Rather, the complex functional anatomy of the head and neck makes it much harder to perform a resection with negative margins. The failure to obtain negative margins is associated with a very poor prognosis. (See",
"    <a class=\"local\" href=\"#H15527726\">",
"     'Surgical margins'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As with soft tissue sarcomas in the extremities, lymph node involvement is uncommon, occurring in only about 10 percent of patients. The most common histologic head and neck subtypes associated with nodal metastases are RMS and angiosarcoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H7798376#H7798376\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Regional nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients who die of soft tissue sarcomas in non-head and neck sites die of metastatic disease. In comparison, those with head and neck sarcomas frequently have local relapse and succumb to their tumor without distant metastatic disease. As an example, in a report of 103 patients with sarcoma of the head and neck treated from 1944 to 1988, locally recurrent disease was the sole cause of death in 65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/6\">",
"     6",
"    </a>",
"    ]. The predominance of local recurrence occurs despite a relatively small average size (4 cm), compared to soft tissue sarcomas in other sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. A major contributor is the difficulty in achieving clear surgical margins. (See",
"    <a class=\"local\" href=\"#H15527726\">",
"     'Surgical margins'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Surgical principles'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15527615\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important prognostic factors are tumor grade and size, status of the surgical margins, and histologic subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/6,7,23,24\">",
"     6,7,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Histologic grade and tumor size",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most series, prognosis is worse in patients with higher-grade and larger tumors. In one study of 154 sarcomas of the head or neck, patients with high-grade lesions were much less likely to be free of disease than were those with low-grade lesions (31 versus 81 percent at a median follow-up of 70 months), as were those with lesions &gt;5 cm in diameter (38 versus 67 percent for smaller lesions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15527726\">",
"    <span class=\"h3\">",
"     Surgical margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive surgical margins are associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/4,6,7,10,18,24\">",
"     4,6,7,10,18,24",
"    </a>",
"    ]. In a series of 146 patients with a variety of skull base sarcomas (both of soft tissue and bone), five-year disease-specific survival rates were 77, 43, and 36 percent for those with negative, close, and positive surgical margins, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/18\">",
"     18",
"    </a>",
"    ]. The presence of",
"    <span class=\"nowrap\">",
"     positive/close",
"    </span>",
"    margins was the only independent predictor of poor survival in multivariate analysis.",
"   </p>",
"   <p>",
"    Negative margins are difficult to achieve in the region of the head and neck because these sarcomas tend to grow in tight anatomic confines and in close proximity to vital neurovascular, bony, or other structures. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Surgical principles'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Histologic subtype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influence of histologic subtype on prognosis was addressed in a report from the Head and Neck Sarcoma registry of the Society of Head and Neck Surgeons, which reported the results of treatment in 214 patients with sarcoma of the head or neck (194 adults and 20 children) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/4\">",
"     4",
"    </a>",
"    ]. Overall disease-free survival was 56 percent at five years. Major determinants of survival were adequacy of resection margins and tumor type (tumor grade was not available). Patients with chondrosarcoma or DFSP had survival approaching 100 percent, while those with MFH or fibrosarcoma had survivals of 60 to 70 percent. Patients with osteosarcoma and angiosarcoma had the worst survival, less than 50 percent at five years.",
"   </p>",
"   <p>",
"    Rhabdomyosarcoma (RMS) and malignant peripheral nerve sheath tumor (MPNST) are particularly aggressive histologic subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/7,9,10,25\">",
"     7,9,10,25",
"    </a>",
"    ]. Prior to modern chemotherapy, RMS was rarely cured. However, using modern combined modality treatment approaches, RMS is curable in over 75 percent of children, and",
"    <span class=\"nowrap\">",
"     orbital/eyelid",
"    </span>",
"    RMS is virtually always cured. Treatment of rhabdomyosarcoma is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34586?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8921486\">",
"    <span class=\"h3\">",
"     Nodal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of nodal metastases worsens prognosis in patients with rhabdomyosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the impact of nodal metastases among patients with other soft tissue sarcomas of the head and neck is unclear; the available data are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/10,27,28\">",
"     10,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15528788\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgical principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their proximity to vital structures and the relatively small space of the head and neck region, surgical removal of head and neck sarcomas often cannot achieve the ideal \"wide\" resection margins that are preferred in other anatomic sites. Other important considerations include the potential for morbidity related to breathing, swallowing and speaking, and the significant cosmetic deformity that may follow neck and facial resections. The quality of the tissue forming the margin is a more important indicator of the risk for local recurrence than is the physical distance from the tumor to the resection margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, the generally accepted recommendation for surgical margins of head and neck sarcomas is to obtain a complete tumor resection with as wide a cuff of normal tissue as is feasible, with as little morbidity as possible.",
"   </p>",
"   <p>",
"    The incidence of cervical lymph node metastases is sufficiently low in head and neck sarcomas that elective neck dissections are generally not indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H7798376#H7798376\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Regional nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with head and neck squamous cell carcinomas, reconstruction with microvascular free flaps has greatly decreased the cosmetic deformity and improved functional results following resection of head and neck sarcomas. Large and critical bone and soft tissue deficits that were once devastating can now be reconstructed with good to excellent results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39815?source=see_link\">",
"     \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8919?source=see_link\">",
"     \"Management of acquired maxillary defects: Prosthetic rehabilitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits of a multidisciplinary approach to surgical and postsurgical treatment cannot be overemphasized. Input from a head and neck oncologic surgeon, a reconstructive surgeon, a speech and swallowing therapist, and a nutritionist are essential for an optimal surgical result. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=see_link\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adjuvant RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When adjuvant radiation therapy (RT) is used for head and neck sarcomas, it is usually administered postoperatively and not prior to an operation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=see_link&amp;anchor=H10#H10\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Preoperative versus postoperative RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits of postoperative RT are controversial. In many studies, patients who receive RT in addition to surgery for bone sarcomas do no better, and perhaps worse, than those receiving surgery alone. As an example, in one meta-analysis of trials for head or neck osteosarcoma, the outcome was best for patients who had surgery alone as compared to surgery plus adjuvant RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/30\">",
"     30",
"    </a>",
"    ]. However, this outcome is at least partly the result of negative selection bias. Patients with a suboptimal excision are more likely to receive RT, and these patients by definition are in a worse prognostic group.",
"   </p>",
"   <p>",
"    On the other hand, retrospective series suggest benefit for adding adjuvant RT to surgery in patients with soft tissue sarcomas of the head and neck, particularly if they are large and high-grade, or low-grade with positive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    close margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/31\">",
"     31",
"    </a>",
"    ]. The experience in extremity sarcomas strongly argues in favor of adjuvant RT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=see_link&amp;anchor=H4#H4\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Benefit of RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of adjuvant RT for the individual sarcoma subtypes is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15528780\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of adjuvant chemotherapy are highly dependent on histologic subtype and discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15528823\">",
"    <span class=\"h1\">",
"     SPECIFIC SUBTYPES, CLINICAL PRESENTATION AND TREATMENT RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation, treatment, and prognosis of specific histologic tumor types will be discussed below. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Osteosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteosarcomas are primary malignant tumors of bone that are characterized by the production of osteoid or immature bone by the malignant cells. Osteosarcoma is the most common primary tumor of bone and about 10 percent of cases arise in the head and neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Only a little over 100 cases of head and neck osteosarcoma are diagnosed annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. In most series, the majority present in the jaw and are about evenly split between the mandible and the maxilla; about 20 percent develop in the extragnathic bones (eg, skull, orbit) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/17,34\">",
"     17,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical patient presents with a mass or swelling in the cheek or jaw, sometimes with pain, and occasionally with dental complaints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/30,32,35-37\">",
"     30,32,35-37",
"    </a>",
"    ]. There is a slight male predominance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. The median age at presentation, 36, is at least 10 years older than that patients with non-head and neck osteosarcomas, although for non-head and neck sarcomas, there is a second peak in incidence in later adulthood that corresponds to secondary Paget disease-related osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/30,36,37\">",
"     30,36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link&amp;anchor=H2#H2\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Head and neck osteosarcomas are typically smaller at presentation than non-head and neck osteosarcomas, and they tend to be of a histologic lower grade than osteosarcomas at other sites (although most are high-grade) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/32,38\">",
"     32,38",
"    </a>",
"    ]. Plain x-rays demonstrate bony destruction with lytic, sclerotic, or mixed lesions, and indistinct margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another difference is the incidence of lung metastases at diagnosis. While patients with extremity osteosarcoma are at very high risk for metastatic involvement of the lungs, lung metastases are less common in patients with jaw osteosarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/17,39,40\">",
"     17,39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link&amp;anchor=H11#H11\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Natural history and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical accessibility plays a significant role in outcome of head and neck osteosarcomas as patients who are able to undergo complete or wide excision have a better prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. As an example, patients with mandibular and maxillary tumors have better survival than do those with disease in the paranasal sinuses or calvarial bones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older series of patients with head and neck osteosarcoma reported five-year survival rates of approximately 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/30,35,37,38,44-48\">",
"     30,35,37,38,44-48",
"    </a>",
"    ]. However, improved outcomes have been seen over time, attributed in part to the introduction of modern multimodality management, which usually includes systemic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/14,39,40,49\">",
"     14,39,40,49",
"    </a>",
"    ]. As an example, one contemporary series of 44 patients, 30 of whom received neoadjuvant chemotherapy, reported three-year overall, disease-specific, and recurrence-free survival rates of 81, 81, and 73 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/42\">",
"     42",
"    </a>",
"    ]. Local control was achieved in 78 percent, a marked improvement over historical series, in which 50 to 65 percent of patients recurred.",
"   </p>",
"   <p>",
"    Local recurrence predominates; distant metastases are less common. As an example, in a meta-analysis that included 163 patients with head and neck osteosarcoma from non-randomized studies, 56 percent recurred; of these, 50 percent recurred locally, 3 percent regionally, and only 20 percent had a component of distant failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/30\">",
"     30",
"    </a>",
"    ]. Other series report somewhat higher rates of distant metastasis (35 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Local recurrences are usually, although not uniformly, fatal. These patients can occasionally be salvaged surgically if wide surgical margins can be attained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rarity of head and neck osteosarcoma and the lack of prospective trials make it difficult to reach valid conclusions regarding optimal treatment.",
"   </p>",
"   <p>",
"    En bloc excision with a margin of normal tissue is the goal of surgical treatment; however, soft tissue margins may be difficult to obtain because of the proximity of critical structures. The soft tissue resection margin can be evaluated intraoperatively by frozen section analysis until either a negative margin is obtained or further resection is not possible. However, the bony margins cannot be microscopically evaluated in this way, and only a gross estimate of the resection margins can be performed intraoperatively. If the permanent sections show a positive bone margin, this should be addressed surgically, if possible, with reresection of the margin soon after the initial procedure.",
"   </p>",
"   <p>",
"    As with other head and neck sarcomas, reconstruction is often best accomplished with microvascular free flap reconstruction. Mandibular and associated soft tissue defects can be reconstructed with a free flap of fibular bone and overlying skin. This minimizes speech, swallowing and cosmetic defects as well as donor site morbidity. Dental implants may be possible after healing is complete. Reconstruction of midface and skull base tumors may require either locoregional rotational flaps for smaller defects or microvascular free flaps (such as the rectus abdominis) for larger defects. Maxillofacial prosthetics may also be necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39815?source=see_link\">",
"     \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8919?source=see_link\">",
"     \"Management of acquired maxillary defects: Prosthetic rehabilitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of achieving clear surgical margins has been consistently demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Adjuvant RT appears to improve survival for patients with positive margins or high-risk features, such as larger tumor size, extensive soft tissue infiltration, and lymphovascular invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2958961\">",
"    <span class=\"h4\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern treatment regimens for osteosarcomas at non head and neck sites generally include systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy to eradicate occult micrometastatic disease. While chemotherapy (given postoperatively [adjuvant] or preoperatively [neoadjuvant]) improves the prognosis of extremity osteosarcoma dramatically, its benefit in osteosarcoma of the head and neck is controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link&amp;anchor=H3#H3\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Adjuvant chemotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link&amp;anchor=H5#H5\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Neoadjuvant versus adjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In uncontrolled case series, the use of adjuvant chemotherapy has been associated with improved survival in patients with head and neck osteosarcomas in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/17,41\">",
"     17,41",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/49\">",
"     49",
"    </a>",
"    ] series. Two meta-analyses on this subject reported conflicting conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/30,50\">",
"     30,50",
"    </a>",
"    ]. Part of the explanation for these disparate results may have been related to incomplete information on the influence of surgical margin status. Nevertheless, in most series, the majority of patients with osteosarcomas of the head and neck have received modern combination chemotherapy, and the improved outcomes over time have been largely attributed to the use of combined modality therapy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Natural history and prognosis'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Whether all patients benefit from chemotherapy is unclear. Some low-grade jaw osteosarcomas may be adequately treated with surgery alone, a long as clear margins can be achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3299381\">",
"    <span class=\"h4\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional osteosarcoma is relatively resistant to radiation therapy (RT), although the small cell variant may be more radiosensitive. Primary RT is usually inadequate to achieve local control, particularly for bulky tumors; surgery is preferred if possible.",
"   </p>",
"   <p>",
"    In patients treated with effective surgery and chemotherapy, adjuvant RT does not improve survival and increases the risk for secondary tumors. However, RT can help provide local control for patients in whom surgical resection with widely negative margins is not possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/34,46,51\">",
"     34,46,51",
"    </a>",
"    ]. Proton beam RT may be particularly useful to treat osteosarcomas that involve the skull base [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link&amp;anchor=H12#H12\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial en bloc excision of the tumor with a wide margin of normal tissue is recommended, if feasible. If the margin is negative, we do not generally give adjuvant RT. If the margin is positive, reexcision should be performed if possible. We utilize adjuvant RT plus concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    chemotherapy for patients who are not candidates for reexcision or if the surgical margins remain positive after reexcision.",
"   </p>",
"   <p>",
"    For patients with larger (&ge;5 cm) or high grade tumors, or positive margins who are able to tolerate it, we recommend adjuvant chemotherapy with an aggressive,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -containing regimen as is used for osteosarcoma of the long bones. As with osteosarcomas at other sites, chemotherapy can be administered preoperative or postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link&amp;anchor=H9#H9\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Choice of regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link&amp;anchor=H5#H5\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Neoadjuvant versus adjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondrosarcomas are a heterogeneous group of malignant bone tumors that share in common the production of chondroid (cartilaginous) matrix. Chondrosarcomas of the head and neck are rarer than osteosarcomas. The head and neck region is reported as the site of origin in 1 to 12 percent of chondrosarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. In contrast to osteosarcomas, chondrosarcomas are more common in the extragnathic bones than in the mandible or maxilla. In a National Cancer Database series of 400 chondrosarcomas of the head and neck diagnosed between 1985 and 1995, 60 percent arose in bone, but only 7 percent of these were in the mandible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chondrosarcomas less commonly develop in cartilage. However, a sufficiently large number develop from laryngeal cartilage so that chondrosarcoma is the most common sarcoma developing in the larynx [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chondrosarcomas are classified according to microscopic appearance. In the report of the National Cancer Data Base of 400 cases, histologic subtypes included conventional (81 percent), myxoid (11 percent), and mesenchymal (9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/56\">",
"     56",
"    </a>",
"    ]. The mesenchymal and myxoid subtypes were rare among Caucasian patients (17 percent) and more common among African Americans and Hispanics (32 and 45 percent, respectively). Histologic classification of chondrosarcomas is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=see_link&amp;anchor=H3#H3\">",
"     \"Chondrosarcoma\", section on 'Classification, histology, and clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment usually consists of wide local excision. The specific anatomic location of chondrosarcomas greatly affects resectability. For example, only recently have skull base chondrosarcomas been removed en bloc using advanced neurosurgical approaches. Such radical procedures may require sacrifice of multiple cranial nerves and necessitate carotid artery occlusion, with its attendant risk of death, stroke, and other significant morbidities. Management of skull base chondrosarcomas is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, chondrosarcomas of the larynx may be excised completely while preserving laryngeal function through a voice-sparing partial laryngectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/58\">",
"     58",
"    </a>",
"    ]. Local recurrences following organ preserving surgery usually require salvage laryngectomy and postoperative radiation therapy.",
"   </p>",
"   <p>",
"    The majority of chondrosarcomas (with the exception of the mesenchymal subtype) are low grade, and long-term survival or cure is achieved with aggressive surgery in most patients. In contrast, high-grade tumors such as mesenchymal chondrosarcoma have a poorer prognosis. In the National Cancer Data Base series, in which 60 percent of patients were treated with surgery alone, and 21 percent received surgery plus radiation therapy, the overall disease-free survival at five and ten years was 87 and 71 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/56\">",
"     56",
"    </a>",
"    ]. The myxoid and mesenchymal subtypes had a worse five year disease-free survival (45 and 53 percent, respectively), as did those with higher grade tumors (67 percent).",
"   </p>",
"   <p>",
"    Other reports note a low (approximately 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]) survival for high grade tumors, largely as a result of distant metastases. In at least one of these series, suboptimal resection may have contributed to the poor outcome; complete resection was only accomplished in one of seven patients with high-grade histology compared to 9 of 10 with low-grade histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited experience with adjuvant (or neoadjuvant) chemotherapy in patients with mesenchymal chondrosarcoma at sites other than the head and neck suggests potential benefit. There are no published reports of effective adjuvant chemotherapy for head and neck chondrosarcomas. Nevertheless, the poor prognosis seen with surgery alone provides a strong argument to discuss the risks and potential benefits of adjuvant doxorubicin-based chemotherapy with these patients as long as they are medically fit and able to tolerate the therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=see_link&amp;anchor=H34#H34\">",
"     \"Chondrosarcoma\", section on 'Mesenchymal chondrosarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unresectable chondrosarcomas (ie, those arising in the cervical spine or base of skull) can be treated with RT, especially proton beam RT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link&amp;anchor=H12#H12\">",
"     \"Chordoma and chondrosarcoma of the skull base\", section on 'Charged particle RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rhabdomyosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyosarcoma (RMS) is a disease that predominantly affects children, and the head and neck area accounts for approximately 35 to 40 percent of all cases. The sites of head and neck RMS can be divided into three main groups: orbit (25 percent), parameningeal area (paranasal sinuses, nasopharynx, nasal cavity, middle",
"    <span class=\"nowrap\">",
"     ear/",
"    </span>",
"    mastoid, and infratemporal fossa; 50 percent), and non orbital non-parameningeal sites (scalp, parotid gland, oral cavity, pharynx, thyroid and parathyroid glands, and neck; 25 percent). &nbsp;",
"   </p>",
"   <p>",
"    The two major histologic subtypes of RMS are embryonal and alveolar. When head and neck RMS arises in the orbit, it is almost always of the embryonal type. A unique form of embryonal RMS, the botryoid variant (sarcoma botryoides), typically arises within the wall of the bladder or vagina, almost exclusively in infants. However, it can arise within the nasopharynx in older children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link&amp;anchor=H9#H9\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\", section on 'Histologic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cases of RMS are reported in adults at all sites, including the head and neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. In a report from the NCI Surveillance, Epidemiology and End Results Database, about 30 percent of head and neck RMS reported between 1973 and 2005 arose in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation is dependent upon tumor location and may include a facial or neck mass, proptosis, nasal discharge, headache, vomiting, change in hearing, vision, speech, swallowing, or respiratory symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18327?source=see_link&amp;anchor=H4#H4\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\", section on 'Head and neck'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Staging and prognostic stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial radiologic evaluation should include computed tomography (CT) scan or magnetic resonance imaging (MRI) of the primary site and surrounding structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/66\">",
"     66",
"    </a>",
"    ]. MRI is increasingly considered the imaging method of choice for certain primary locations, such as the head and neck, because of its multiplanar capacity, ability to attenuate bone artifact, and superior soft tissue contrast. While CT scan may best identify lung metastases, whole body MRI or integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scans efficiently evaluate bone, soft tissue, and parenchymal organs. Brain metastases are rare; thus brain imaging is reserved for patients with clinical suspicion. Since parameningeal tumors may show earlier spread to the skull base and the intracranial compartment, lumbar puncture should be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18327?source=see_link&amp;anchor=H16#H16\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\", section on 'Lumbar puncture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two different staging systems are used in conjunction by the Intergroup Rhabdomyosarcoma Study Group",
"    <span class=\"nowrap\">",
"     (IRSG)/Children's",
"    </span>",
"    Oncology Group (COG) for the purpose of estimating prognosis and assigning risk-directed treatment. The IRSG Clinical Group (CG) system recognizes four disease categories (Group I through IV) that are based upon the degree of tumor spread at diagnosis and the amount of disease remaining after initial surgery (",
"    <a class=\"graphic graphic_table graphicRef59875 \" href=\"mobipreview.htm?31/41/32411\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although the CG system is clinically useful for assigning treatment, it does not take into account other important prognostic factors, such as tumor size and primary site, disease extent, histology, and patient age. A site-based tumor-node-metastasis (TNM) staging system was incorporated for assessing prognosis and assigning therapy in conjunction with the traditional surgicopathologic clinical grouping system (",
"    <a class=\"graphic graphic_table graphicRef62717 \" href=\"mobipreview.htm?7/13/7389\">",
"     table 3",
"    </a>",
"    ). Although there are clear prognostic differences based upon the site of origin, within the head and neck, prognosis is more specifically dependent upon location than TNM stage and upon other factors such as age and histologic type.",
"   </p>",
"   <p>",
"    Both the CG and TNM stage as well as several other clinicopathologic variables are included in a prognostic stratification system that is used to select treatment based upon the estimated prognosis (risk-adapted therapy, (",
"    <a class=\"graphic graphic_table graphicRef71404 \" href=\"mobipreview.htm?10/52/11086\">",
"     table 4",
"    </a>",
"    )). RMS of the orbit and eyelid are considered favorable prognosis sites, while parameningeal tumors are considered unfavorable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18327?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Natural history and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to 1970, the outlook for children with RMS was dismal, with cure rates of 20 percent from surgery, with or without radiation therapy (RT). Outcomes have markedly improved with the addition of systemic chemotherapy, with reported five-year survival rates of 50 to 75 percent for patients with head and neck parameningeal disease and 70 to 80 percent for patients with non-parameningeal head and neck disease sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognosis also depends upon the site of presentation and age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with neck primaries may have a worse prognosis than those with tumors arising in other sites of the head and neck, with a higher local and distant relapse rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The influence of disease subsite was addressed in a SEER database review of 558 cases of head and neck RMS reported between 1973 and 2007 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/70\">",
"       70",
"      </a>",
"      ]. Five-year survival for orbital, non-orbital non-parameningeal, and parameningeal sites was 84, 70, and 49 percent, respectively.",
"     </li>",
"     <li>",
"      As a group, adults probably have a worse prognosis than do children with RMS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/64,71-73\">",
"       64,71-73",
"      </a>",
"      ]. The poorer outcomes in adults may, in part, reflect the inadequacy of primary treatment. However, adults are also more likely to present with advanced disease. As an example, in one series of 26 adults with head and neck RMS, 69 percent were stage III or IV at presentation, and the five year survival rate for all patients was 8 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/71\">",
"       71",
"      </a>",
"      ]. In contrast, in the IRSG studies, fewer than 15 percent of children had stage IV disease, and the cure rate with multimodality therapy was about 70 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/67,74,75\">",
"       67,74,75",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34586?source=see_link&amp;anchor=H30#H30\">",
"       \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\", section on 'Treatment of adults'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A critical issue for the predominantly young patient with RMS, most of whom will survive the cancer, is late complications from therapy. For head and neck sites, this includes short stature or facial asymmetry in almost one-third of long-term survivors, poor dentition in one-fourth, and impaired vision, hearing, and learning, each in one-sixth of survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34586?source=see_link&amp;anchor=H31#H31\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\", section on 'Long-term complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Overview of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of RMS is complex, and typically involves surgery, RT, and multi-agent chemotherapy. If appropriate, children should be offered treatment on a clinical trial. The results of five large IRSG treatment studies (IRS I-V), enrolling the majority of American children with RMS, have established many of the general principles that guide modern management of RMS. These are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34586?source=see_link&amp;anchor=H3#H3\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\", section on 'Overview of IRSG I-V study results'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following represent general principles of management for RMS of the head and neck:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete excision should be considered for localized disease as long as functional",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cosmetic results are acceptable. However, primary head and neck tumors are rarely amenable to wide local excision because of proximity to vital structures and cosmetic concerns. The availability of highly skilled otolaryngologic and craniofacial reconstructive teams may permit resection of some tumors that would otherwise be considered unresectable.",
"     </li>",
"     <li>",
"      Routine lymph node sampling is not indicated. Because of the low incidence of locoregional lymph node involvement, routine cervical lymph node sampling is unnecessary except for parameningeal sites.",
"     </li>",
"     <li>",
"      The Children's Oncology Group (COG, into which IRSG was merged) has developed risk-adapted therapy guidelines to assist in treatment decisions for adjuvant RT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      adjuvant chemotherapy, including selection of chemotherapy regimen (",
"      <a class=\"graphic graphic_table graphicRef71404 \" href=\"mobipreview.htm?10/52/11086\">",
"       table 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Although RT for RMS is commonly delivered through external beam RT, for children with small, critically located tumors in the head and neck, intracavitary or interstitial implants (brachytherapy) may be an option [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/68,77\">",
"       68,77",
"      </a>",
"      ]. Brachytherapy may allow dose intensification by delivering RT to a restricted tissue volume, with preservation of anatomy and organ function, and with decreased late effects by minimizing scatter to adjacent structures. Brachytherapy may also have a role in salvage treatment of recurrent disease.",
"     </li>",
"     <li>",
"      Adults with RMS should be treated in a manner analogous to children, with chemotherapy regimens adjusted appropriately.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed overview of the treatment of rhabdomyosarcoma in childhood and adolescence is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34586?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Angiosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiosarcomas are tumors arising in either blood or lymphatic vessels. They account for about 15 percent of all head and neck sarcomas and 1 percent of all soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/4,7,9\">",
"     4,7,9",
"    </a>",
"    ]. The scalp and face are the most common sites of origin. In a SEER database series of 434 cases of cutaneous angiosarcomas reported between 1973 and 2007, 270 (72 percent) arose in the region of the head and neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/78\">",
"     78",
"    </a>",
"    ]. Head and neck angiosarcomas tend to be a disease of older Caucasian men, with a median age of incidence of 65 to 70, and a male to female ratio of 2:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/9,10,78-83\">",
"     9,10,78-83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative Caucasian male predominance, age of incidence, and localization to the face and scalp has led some to propose that sun exposure contributes to the etiology, but this has not been clearly demonstrated. A prior history of radiotherapy to the face or scalp is elicited in 5 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/79,80,84\">",
"     79,80,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients typically present with a blue or purple lesion on the scalp or face that has been present for several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. These lesions may appear macular, nodular, or plaque-like. Diffuse, clinically undetectable intradermal spread leads to indistinct borders and a high incidence of multicentricity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/85\">",
"     85",
"    </a>",
"    ]. Advanced lesions can show hemorrhage or ulceration. Cervical lymphadenopathy is found in approximately 10 percent of patients at the time of presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Natural history and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outlook for these tumors is poor, with five year survival generally less than 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/78,79,82,86-88\">",
"     78,79,82,86-88",
"    </a>",
"    ]. As an example, in a series of 133 angiosarcomas of the scalp and neck reported to the SEER database between 1973 and 2007, five and ten-year survival rates were 34 and 14 percent, respectively. Local recurrence is a major problem, but distant metastases are also frequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/82,87,88\">",
"     82,87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important prognostic factor for survival in patients with head and neck angiosarcoma is size and the ability to completely resect the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/79-82,87,89\">",
"     79-82,87,89",
"    </a>",
"    ]. Patients with tumors less than 5 cm in diameter have better overall survival and a lower risk of regional recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/79-81,89,90\">",
"     79-81,89,90",
"    </a>",
"    ]. In addition, cellular epithelioid morphology is emerging as a potentially adverse prognostic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence, other than case series, upon which to base treatment recommendations for angiosarcoma of the head and neck. Complete surgical resection with wide margins is preferred for local and locoregional disease. Although the risk of lymph node spread is higher with angiosarcomas than with other head and neck sarcomas, the overall risk remains lower than what is generally considered an indication for elective lymph node dissection. As a result, most surgeons reserve neck treatment for gross nodal disease only.",
"   </p>",
"   <p>",
"    Reconstruction is performed immediately following resection; even sizable deficits can be reconstructed using current techniques. Radial forearm and rectus abdominis microvascular free flaps can cover large surface defects with minimal donor site morbidity. Smaller defects can be reconstructed using skin grafts, or local or regional flaps. Some surgeons perform small mapping biopsies along the proposed margins preoperatively so that disease with subclinical microscopic spread can be identified and appropriate ablative and reconstructive planning undertaken prior to definitive resection.",
"   </p>",
"   <p>",
"    Due to the propensity for insidious local infiltration, resection should be combined in nearly all cases by preoperative or postoperative radiation therapy (RT). Although randomized trials are not available, the benefits of RT are supported by several small reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/79-81,85,90\">",
"     79-81,85,90",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 28 patients with angiosarcoma of the head and neck treated at UCLA, only 1 of 12 patients treated with surgery alone remained disease-free compared with four of six who received postoperative RT, with or without chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report of 70 patients with nonmetastatic angiosarcoma of the face and scalp, combined therapy with surgery plus RT (versus surgery alone or RT alone) was associated with improved overall survival (68 versus 32 percent), disease-specific survival (76 versus 33 percent) as well as better local control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/90\">",
"       90",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of adjuvant chemotherapy, either alone or concurrent with RT, is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/91-93\">",
"     91-93",
"    </a>",
"    ]. In the above cited series of 70 patients with nonmetastatic angiosarcoma, outcomes were not significantly better in those who received any chemotherapy in addition to local therapy (five-year overall survival 45 versus 39 percent, p = 0.54) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, interest is increasing in neoadjuvant chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT as a component of combined modality therapy, which may allow some patients to undergo potentially less mutilating surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/87,94\">",
"     87,94",
"    </a>",
"    ]. For patients with unresectable tumors or those who refuse surgery, definitive RT or chemoradiation is an option.",
"   </p>",
"   <p>",
"    Anthracyclines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , and taxanes, as single agents or in combination regimens are used to treat metastatic angiosarcoma. In contrast to other soft-tissue sarcomas, angiosarcomas appear to be particularly responsive to taxanes. In addition, promising responses, occasionally dramatic, have been demonstrated in very limited number of angiosarcoma patients with various biological molecules, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , interferon, and interleukin 2, either as single agents or in combination with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/93,95\">",
"     93,95",
"    </a>",
"    ]. Systemic therapy for advanced soft tissue sarcoma, including angiosarcoma, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/11/41146?source=see_link\">",
"     \"Systemic treatment of metastatic soft tissue sarcoma\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Desmoids and dermatofibrosarcoma protuberans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both of these tumors are locally aggressive. Desmoid tumors (also called aggressive fibromatosis) are benign, slowly growing neoplasms arising from fibroblastic stromal elements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/96\">",
"     96",
"    </a>",
"    ]. Although locally aggressive, with a propensity for local recurrence, even after complete resection, they do not have the capacity to establish metastatic lesions. Desmoids can be lethal, particularly in the abdominal cavity, due to local invasive behavior. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dermatofibrosarcoma protuberans (DFSP) is a low to intermediate-grade cutaneous sarcoma that is characterized by a translocation involving chromosomes 17 and 22. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=see_link&amp;anchor=H3#H3\">",
"     \"Dermatofibrosarcoma protuberans\", section on 'Molecular pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DFSP is most common in adults who are 20 to 30 years of age, but has also been described in children. The tumor often presents as a firm, solitary, slowly enlarging, cutaneous nodule between 2 and 5 cm in size. The scalp and neck (supraclavicular fossa) are the most common sites in the head and neck. As with other sites, DFSP of the head and neck has a marked propensity for local recurrence but is typically associated with long term survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/4,7,9\">",
"     4,7,9",
"    </a>",
"    ]. Metastatic disease occurs in less than 6 percent of cases and is usually preceded by two or more local recurrences. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=see_link&amp;anchor=H19#H19\">",
"     \"Dermatofibrosarcoma protuberans\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fibrosarcomatous variant represents an uncommon form of DFSP that is associated with a significantly more aggressive clinical course. The Bednar variant of this tumor is even less common and is distinguished histologically by the dispersal of melanin-containing cells in an otherwise typical DFSP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=see_link&amp;anchor=H4#H4\">",
"     \"Dermatofibrosarcoma protuberans\", section on 'Histology and histogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for desmoids involves complete excision when possible and radiation for recurrent, marginally resectable, or unresectable tumors. There may be a role for chemotherapy or hormonal therapy in patients with unresectable or recurrent desmoid tumors. Although close observation is an acceptable strategy for stable asymptomatic desmoids, treatment is indicated for symptomatic patients, if there is imminent risk to adjacent structures or if the tumor creates cosmetic concerns; if observation is chosen, followup should be frequent to avoid substantial disease progression that can be associated with high morbidity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=see_link\">",
"     \"Desmoid tumors: Systemic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The preferred initial treatment for DFSP of the head and neck is resection with pathologically negative margins. As with DFSP at other sites, approximately 33 to 50 percent of patients experience local recurrence after local excision, often within three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/97\">",
"     97",
"    </a>",
"    ]. Wide excision with 3 cm margins, when possible, of visibly uninvolved tissue and inclusion of superficial fascia produces better clearance rates, but with a corresponding loss of tissue. Although data are limited, treatment with Moh's micrographic surgery may permit greater local control while minimizing the amount of normal tissue that must be sacrificed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/98-100\">",
"     98-100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although DFSP is a radioresponsive tumor, radiation therapy (RT) is only rarely used as a primary treatment. Although adjuvant radiation is often recommended for patients with positive resection margins, there is no consensus regarding the role of adjuvant radiotherapy for patients with completely resected disease, since its benefit is limited to improved local control but not improved overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accumulating evidence supports the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in treating DFSP. The majority of DFSPs have a translocation involving chromosomes 17 and 22, which places PDGFB under the control of the COL1A1 promoter, leading to constitutive activation of the PDGF receptor (PDGFR), a receptor tyrosine kinase. Orally active small molecule tyrosine kinase inhibitors such as imatinib inhibit the PDGFR. Imatinib is approved in the United States and Europe for use in adult patients who have unresectable, recurrent,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastatic DFSP, either alone or in combination with surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=see_link&amp;anchor=H23#H23\">",
"     \"Dermatofibrosarcoma protuberans\", section on 'Imatinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Other adult soft tissue sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 percent of all head and neck sarcomas do not fit into any of the above categories. These include a variety of histologies (pleomorphic sarcoma [previously called MFH], fibrosarcoma, MPNST, synovial sarcoma, LMS, liposarcoma, etc) and they can arise from any site in the head and neck. Unlike soft tissue sarcomas at other sites, those involving the head or neck more often cause death by local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/6\">",
"     6",
"    </a>",
"    ]. Synovial sarcomas involving sites in the head and neck appear to behave more aggressively than those involving the extremities, and prognosis is generally less favorable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/102-104\">",
"     102-104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study examined prognostic factors and implications for treatment in 103 patients with soft tissue sarcomas of the head or neck who were treated from 1944 to 1988 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/6\">",
"     6",
"    </a>",
"    ]. Forty-six percent had stage IIIa or IIIb disease (",
"    <a class=\"graphic graphic_table graphicRef66617 \" href=\"mobipreview.htm?23/13/23773\">",
"     table 5",
"    </a>",
"    ). Neck primaries occurred in 23 percent, with a variety of other sites accounting for the remainder. MFH was the most common histologic subtype. The primary treatment was surgery in 45 percent, surgery plus RT in 37 percent, and RT alone in 18 percent. Overall five year survival was 50 percent. The five year local control rate was only 47 percent, and local tumor was the cause of death in 63 percent. In multivariate analysis, the only independent prognostic factor for survival was the ability to perform excisional surgery. Local control was better for patients with tumors of the head than of the neck, and better for patients receiving RT plus surgery versus RT or surgery alone. Younger patients had a better outcome than older patients.",
"   </p>",
"   <p>",
"    Treatment principles for these tumors should ideally follow those used for tumors outside of the head and neck region:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extirpative surgery with wide margins should be employed when possible. Some suggest that a 2 cm margin is optimal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/105\">",
"       105",
"      </a>",
"      ], but this is not attainable at all anatomic sites.",
"     </li>",
"     <li>",
"      In general, adjuvant RT improves local control and should be recommended for all high-grade tumors and any malignant tumor (even low-grade) treated with less than wide margin excisional surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/31,106-109\">",
"       31,106-109",
"      </a>",
"      ]. Although experience is limited, preoperative radiotherapy appears to be associated with fewer acute postoperative wound complications than in extremity sites and may permit lower doses of RT to be used while providing a high rate of local control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/110\">",
"       110",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=see_link&amp;anchor=H10#H10\">",
"       \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Preoperative versus postoperative RT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unresectable tumors should be treated with RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/31\">",
"       31",
"      </a>",
"      ]. More often, this will result in palliative benefit rather than cure.",
"     </li>",
"     <li>",
"      The role of adjuvant chemotherapy for head and neck sarcomas is unknown. For high-grade, large extremity sarcomas, the benefit of chemotherapy is controversial, and data from individual trials and meta-analyses suggest that a survival benefit, if it exists, is small. However, a meta-analysis suggests improved local control with adjuvant chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/111\">",
"       111",
"      </a>",
"      ], which may be relevant for sarcomas that occur in the head and neck, for which local recurrence is the main cause of treatment failure. The discussion and decisions about adjuvant chemotherapy should be individualized but only take place with patients who have a good performance status. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14521?source=see_link\">",
"       \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=see_link\">",
"       \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the absence of demonstrable metastases, local recurrences should be treated aggressively, as they can occasionally be salvaged by further surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/50/34602/abstract/31,112\">",
"       31,112",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15527453\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATION",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head and neck sarcomas are relatively rare tumors, accounting for only about 2 percent of all head and neck malignancies and for 4 to 10 percent of all sarcomas.",
"     </li>",
"     <li>",
"      Patients generally present with a palpable mass (especially in the neck), skin changes (especially on the scalp or face), or subsite-specific symptoms (eg, hoarseness with laryngeal primaries, dysphagia with oropharyngeal tumors, epistaxis, nasal obstruction, or cranial nerve deficits with skull base tumors). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation and diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients suspected of having a head or neck sarcoma, magnetic resonance imaging (MRI) is the superior neuroimaging study, although in many cases, CT scanning complements MRI and both are helpful in surgical planning. Pretreatment evaluation should also include a directed metastatic workup. The diagnostic biopsy method should be carefully planned in conjunction with the surgeon who will perform the definitive surgery. (See",
"      <a class=\"local\" href=\"#H15528177\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the natural history of these tumors parallels that of their non-head and neck counterparts, but with a higher rate of local recurrence after treatment and lower overall survival rates. The major prognostic factors are histologic grade, tumor size, status of the surgical margins, and histologic subtype. (See",
"      <a class=\"local\" href=\"#H15528150\">",
"       'Natural history, and prognostic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of their proximity to vital structures and the relatively small space of the head and neck region, surgical removal of head and neck sarcomas often cannot achieve the ideal \"wide\" resection margins that are preferred in other anatomic sites, and there are important considerations for morbidity related to breathing, swallowing and speaking, and the significant cosmetic deformity that may follow neck and facial resections. The generally accepted recommendation for surgical margins of head and neck sarcomas is to obtain a complete tumor resection with as wide a cuff of normal tissue as is feasible, with as little morbidity as possible. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Surgical principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25334872\">",
"    <span class=\"h2\">",
"     Specific histologic subtypes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteosarcomas most commonly arise in the jaw. Initial treatment should consist of en bloc excision of the tumor with a wide margin of normal tissue, if feasible. For patients with positive surgical margins, reexcision is preferred, if possible. If the margin is still positive after reexcision or if reexcision is not feasible, we suggest adjuvant radiotherapy with concomitant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      as a radiation sensitizer (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with negative resection margins, we suggest not pursuing adjuvant RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with larger (&gt;5 cm) or high-grade tumors, or positive margins who are able to tolerate it, we suggest adjuvant chemotherapy using an aggressive cisplatin-based regimen as used for osteosarcomas arising at other sites (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients with smaller or low grade tumors we suggest not pursuing adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link&amp;anchor=H3#H3\">",
"       \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Adjuvant chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chondrosarcomas are more common in the extragnathic bones than in the mandible or maxilla, but a significant number develop from laryngeal cartilage. The majority are low grade, and long-term survival or cure is achieved with wide local excision in most patients. Laryngeal chondrosarcomas may be amenable to complete excision with preserved laryngeal function through a voice-sparing partial laryngectomy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For the rare patient with a mesenchymal chondrosarcoma of the head and neck, the poor prognosis seen with surgery alone provides a strong argument to discuss the potential benefits of adjuvant doxorubicin-based chemotherapy as long as they are medically fit and able to tolerate the therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=see_link&amp;anchor=H34#H34\">",
"       \"Chondrosarcoma\", section on 'Mesenchymal chondrosarcoma'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Unresectable chondrosarcomas (eg, those arising at the skull base or upper cervical spine) should be treated with RT, especially proton beam RT. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link&amp;anchor=H12#H12\">",
"       \"Chordoma and chondrosarcoma of the skull base\", section on 'Charged particle RT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rhabdomyosarcoma is predominantly a disease of children; 35 to 40 percent of primary sites are in the head and neck. Complete excision should be considered for localized disease as long as functional",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cosmetic results are acceptable. Risk-adapted therapy guidelines assist in treatment decisions for adjuvant RT and adjuvant chemotherapy, including selection of chemotherapy regimen (",
"      <a class=\"graphic graphic_table graphicRef71404 \" href=\"mobipreview.htm?10/52/11086\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Rhabdomyosarcoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angiosarcomas are aggressive tumors arising in either blood or lymphatic vessels; the scalp and face are the most common sites of origin. Complete surgical resection with wide margins is preferred for local and locoregional disease. Due to the propensity for insidious local infiltration, we suggest preoperative or postoperative radiation therapy (RT) for almost all patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The role of adjuvant chemotherapy is unclear, and we do not recommend it routinely. Neoadjuvant chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT may allow some patients with locally advanced lesions to undergo potentially less mutilating surgery. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Angiosarcoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Desmoid tumors and dermatofibrosarcoma protuberans (DFSP) are locally aggressive neoplasms with a propensity for local recurrence despite complete resection. Close observation is an acceptable strategy for stable, asymptomatic desmoids, but treatment (complete excision when possible, and radiation for recurrent, marginally resectable, or unresectable tumors) is indicated for symptomatic patients, if there is imminent risk to adjacent structures, or if the tumor creates cosmetic concerns. There may be a role for chemotherapy, or hormonal therapy in patients with unresectable or recurrent desmoid tumors, and for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      in patients with recurrent DFSP.",
"      <br/>",
"      <br/>",
"      The preferred initial treatment for DFSP of the head and neck is resection with pathologically negative margins. Although available data are limited, Moh&rsquo;s micrographic surgery may permit greater local control while minimizing the amount of normal tissue that must be sacrificed. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Desmoids and dermatofibrosarcoma protuberans'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For other adult-type soft tissue sarcomas that do not fit into any of these categories, treatment principles for these tumors should follow those used for tumors outside of the head and neck region. Extirpative surgery with wide margins is preferred, if feasible. We recommend adjuvant RT (either preoperative or postoperative) for all high-grade tumors and any malignant tumor (even low-grade) treated with less than wide margin excisional surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The benefit of adjuvant chemotherapy following optimal local therapy remains uncertain. We do not routinely pursue this approach for soft tissue sarcomas arising in the head and neck; however, it may be considered for patients with a good performance status who are at high risk of a local recurrence. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Other adult soft tissue sarcomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/1\">",
"      Kraus DH, Dubner S, Harrison LB, et al. Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas. Cancer 1994; 74:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/2\">",
"      Hoffman HT, Robinson RA, Spiess JL, Buatti J. Update in management of head and neck sarcoma. Curr Opin Oncol 2004; 16:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/3\">",
"      Potter BO, Sturgis EM. Sarcomas of the head and neck. Surg Oncol Clin N Am 2003; 12:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/4\">",
"      Wanebo HJ, Koness RJ, MacFarlane JK, et al. Head and neck sarcoma: report of the Head and Neck Sarcoma Registry. Society of Head and Neck Surgeons Committee on Research. Head Neck 1992; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/5\">",
"      Odell PF. Head and neck sarcomas: a review. J Otolaryngol 1996; 25:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/6\">",
"      Eeles RA, Fisher C, A'Hern RP, et al. Head and neck sarcomas: prognostic factors and implications for treatment. Br J Cancer 1993; 68:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/7\">",
"      Weber RS, Benjamin RS, Peters LJ, et al. Soft tissue sarcomas of the head and neck in adolescents and adults. Am J Surg 1986; 152:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/8\">",
"      Kowalski LP, San CI. Prognostic factors in head and neck soft tissue sarcomas: analysis of 128 cases. J Surg Oncol 1994; 56:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/9\">",
"      Freedman AM, Reiman HM, Woods JE. Soft-tissue sarcomas of the head and neck. Am J Surg 1989; 158:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/10\">",
"      Farhood AI, Hajdu SI, Shiu MH, Strong EW. Soft tissue sarcomas of the head and neck in adults. Am J Surg 1990; 160:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/11\">",
"      Figueiredo MT, Marques LA, Campos-Filho N. Soft-tissue sarcomas of the head and neck in adults and children: experience at a single institution with a review of literature. Int J Cancer 1988; 41:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/12\">",
"      Greager JA, Das Gupta TK. Adult head and neck soft-tissue sarcomas. Otolaryngol Clin North Am 1986; 19:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/13\">",
"      Rao BN, Santana VM, Fleming ID, et al. Management and prognosis of head and neck sarcomas. Am J Surg 1989; 158:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/14\">",
"      Ketabchi A, Kalavrezos N, Newman L. Sarcomas of the head and neck: a 10-year retrospective of 25 patients to evaluate treatment modalities, function and survival. Br J Oral Maxillofac Surg 2011; 49:116.",
"     </a>",
"    </li>",
"    <li>",
"     Wexler LH, Meyer WH, Helman LJ. Rhabdomyosarcoma. In: Principles and practice of pediatric oncology, 6th, Pizzo PA, Poplack DG.  (Eds), Lippincott, Williams, and Wilkins, Philadelphia 2011. p.923.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/16\">",
"      Sale KA, Wallace DI, Girod DA, Tsue TT. Radiation-induced malignancy of the head and neck. Otolaryngol Head Neck Surg 2004; 131:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/17\">",
"      Jasnau S, Meyer U, Potratz J, et al. Craniofacial osteosarcoma Experience of the cooperative German-Austrian-Swiss osteosarcoma study group. Oral Oncol 2008; 44:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/18\">",
"      Gil Z, Patel SG, Singh B, et al. Analysis of prognostic factors in 146 patients with anterior skull base sarcoma: an international collaborative study. Cancer 2007; 110:1033.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines available at www.nccn.org (Accessed on November 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/20\">",
"      Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/21\">",
"      Hajdu SI, Shiu MH, Brennan MF. The role of the pathologist in the management of soft tissue sarcomas. World J Surg 1988; 12:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/22\">",
"      Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003; 97:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/23\">",
"      Huber GF, Matthews TW, Dort JC. Soft-tissue sarcomas of the head and neck: a retrospective analysis of the Alberta experience 1974 to 1999. Laryngoscope 2006; 116:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/24\">",
"      Tran LM, Mark R, Meier R, et al. Sarcomas of the head and neck. Prognostic factors and treatment strategies. Cancer 1992; 70:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/25\">",
"      Minovi A, Basten O, Hunter B, et al. Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review. Head Neck 2007; 29:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/26\">",
"      Pappo AS, Meza JL, Donaldson SS, et al. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV. J Clin Oncol 2003; 21:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/27\">",
"      Smith VA, Overton LJ, Lentsch EJ. Head and neck soft tissue sarcomas: unique lack of significance of synchronous node metastases. J Surg Oncol 2012; 106:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/28\">",
"      de Bree R, van der Valk P, Kuik DJ, et al. Prognostic factors in adult soft tissue sarcomas of the head and neck: a single-centre experience. Oral Oncol 2006; 42:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/29\">",
"      Rydholm A. Surgical margins for soft tissue sarcoma. Acta Orthop Scand Suppl 1997; 273:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/30\">",
"      Kassir RR, Rassekh CH, Kinsella JB, et al. Osteosarcoma of the head and neck: meta-analysis of nonrandomized studies. Laryngoscope 1997; 107:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/31\">",
"      Mendenhall WM, Mendenhall CM, Werning JW, et al. Adult head and neck soft tissue sarcomas. Head Neck 2005; 27:916.",
"     </a>",
"    </li>",
"    <li>",
"     Unni KK. Osteosarcoma - General aspects and data on 11,087 cases. In: Dahlin's Bone Tumors, Unni KK (Ed), Lippincott-Raven, Philadelphia 1996. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/33\">",
"      Albright JT, Topham AK, Reilly JS. Pediatric head and neck malignancies: US incidence and trends over 2 decades. Arch Otolaryngol Head Neck Surg 2002; 128:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/34\">",
"      Guadagnolo BA, Zagars GK, Raymond AK, et al. Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment. Cancer 2009; 115:3262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/35\">",
"      Tanzawa H, Uchiyama S, Sato K. Statistical observation of osteosarcoma of the maxillofacial region in Japan. Analysis of 114 Japanese cases reported between 1930 and 1989. Oral Surg Oral Med Oral Pathol 1991; 72:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/36\">",
"      Garrington GE, Scofield HH, Cornyn J, Hooker SP. Osteosarcoma of the jaws. Analysis of 56 cases. Cancer 1967; 20:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/37\">",
"      Caron AS, Hajdu SI, Strong EW. Osteogenic sarcoma of the facial and cranial bones. A review of forty-three cases. Am J Surg 1971; 122:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/38\">",
"      Clark JL, Unni KK, Dahlin DC, Devine KD. Osteosarcoma of the jaw. Cancer 1983; 51:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/39\">",
"      Huh WW, Holsinger FC, Levy A, et al. Osteosarcoma of the jaw in children and young adults. Head Neck 2012; 34:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/40\">",
"      DeAngelis AF, Spinou C, Tsui A, et al. Outcomes of patients with maxillofacial osteosarcoma: a review of 15 cases. J Oral Maxillofac Surg 2012; 70:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/41\">",
"      Laskar S, Basu A, Muckaden MA, et al. Osteosarcoma of the head and neck region: lessons learned from a single-institution experience of 50 patients. Head Neck 2008; 30:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/42\">",
"      Patel SG, Meyers P, Huvos AG, et al. Improved outcomes in patients with osteogenic sarcoma of the head and neck. Cancer 2002; 95:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/43\">",
"      Granados-Garcia M, Luna-Ortiz K, Castillo-Oliva HA, et al. Free osseous and soft tissue surgical margins as prognostic factors in mandibular osteosarcoma. Oral Oncol 2006; 42:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/44\">",
"      Russ JE, Jesse RH. Management of osteosarcoma of the maxilla and mandible. Am J Surg 1980; 140:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/45\">",
"      Bertoni F, Dallera P, Bacchini P, et al. The Istituto Rizzoli-Beretta experience with osteosarcoma of the jaw. Cancer 1991; 68:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/46\">",
"      Mark RJ, Sercarz JA, Tran L, et al. Osteogenic sarcoma of the head and neck. The UCLA experience. Arch Otolaryngol Head Neck Surg 1991; 117:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/47\">",
"      Vege DS, Borges AM, Aggrawal K, et al. Osteosarcoma of the craniofacial bones. A clinico-pathological study. J Craniomaxillofac Surg 1991; 19:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/48\">",
"      Ryan RF, Eisenstadt S, Shambaugh EM. Osteogenic sarcoma of the mandible: a plea for radical initial surgery. Plast Reconstr Surg 1986; 78:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/49\">",
"      Smith RB, Apostolakis LW, Karnell LH, et al. National Cancer Data Base report on osteosarcoma of the head and neck. Cancer 2003; 98:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/50\">",
"      Smeele LE, Kostense PJ, van der Waal I, Snow GB. Effect of chemotherapy on survival of craniofacial osteosarcoma: a systematic review of 201 patients. J Clin Oncol 1997; 15:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/51\">",
"      Canadian Society of Otolaryngology-Head and Neck Surgery Oncology Study Group. Osteogenic sarcoma of the mandible and maxilla: a Canadian review (1980-2000). J Otolaryngol 2004; 33:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/52\">",
"      DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005; 61:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/53\">",
"      Garrington GE, Collett WK. Chondrosarcoma. I. A selected literature review. J Oral Pathol 1988; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/54\">",
"      Ruark DS, Schlehaider UK, Shah JP. Chondrosarcomas of the head and neck. World J Surg 1992; 16:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/55\">",
"      Vener J, Rice DH, Newman AN. Osteosarcoma and chondrosarcoma of the head and neck. Laryngoscope 1984; 94:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/56\">",
"      Koch BB, Karnell LH, Hoffman HT, et al. National cancer database report on chondrosarcoma of the head and neck. Head Neck 2000; 22:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/57\">",
"      Kozelsky TF, Bonner JA, Foote RL, et al. Laryngeal chondrosarcomas: the Mayo Clinic experience. J Surg Oncol 1997; 65:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/58\">",
"      Thompson LD, Gannon FH. Chondrosarcoma of the larynx: a clinicopathologic study of 111 cases with a review of the literature. Am J Surg Pathol 2002; 26:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/59\">",
"      Mark RJ, Tran LM, Sercarz J, et al. Chondrosarcoma of the head and neck. The UCLA experience, 1955-1988. Am J Clin Oncol 1993; 16:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/60\">",
"      Finn DG, Goepfert H, Batsakis JG. Chondrosarcoma of the head and neck. Laryngoscope 1984; 94:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/61\">",
"      Burkey BB, Hoffman HT, Baker SR, et al. Chondrosarcoma of the head and neck. Laryngoscope 1990; 100:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/62\">",
"      Ohba S, Matsumoto F, Fujimaki M, et al. Embryonal rhabdomyosarcoma of the head and neck in an adult. Auris Nasus Larynx 2012; 39:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/63\">",
"      Kukwa W, Wojtowicz P, Jagielska B, et al. Laryngeal embryonal rhabdomyosarcoma in an adult - a case presentation in the eyes of geneticists and clinicians. BMC Cancer 2011; 11:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/64\">",
"      Wagemans J, Beuselinck B, Nuyts S, et al. A case series of embryonal rhabdomyosarcoma of the head and neck in adults. Acta Clin Belg 2010; 65:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/65\">",
"      Sultan I, Qaddoumi I, Yaser S, et al. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol 2009; 27:3391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/66\">",
"      Freling NJ, Merks JH, Saeed P, et al. Imaging findings in craniofacial childhood rhabdomyosarcoma. Pediatr Radiol 2010; 40:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/67\">",
"      Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/68\">",
"      Blank LE, Koedooder K, Pieters BR, et al. The AMORE protocol for advanced-stage and recurrent nonorbital rhabdomyosarcoma in the head-and-neck region of children: a radiation oncology view. Int J Radiat Oncol Biol Phys 2009; 74:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/69\">",
"      Wharam MD Jr, Foulkes MA, Lawrence W Jr, et al. Soft tissue sarcoma of the head and neck in childhood: nonorbital and nonparameningeal sites. A report of the Intergroup Rhabdomyosarcoma Study (IRS)-I. Cancer 1984; 53:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/70\">",
"      Turner JH, Richmon JD. Head and neck rhabdomyosarcoma: a critical analysis of population-based incidence and survival data. Otolaryngol Head Neck Surg 2011; 145:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/71\">",
"      Nayar RC, Prudhomme F, Parise O Jr, et al. Rhabdomyosarcoma of the head and neck in adults: a study of 26 patients. Laryngoscope 1993; 103:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/72\">",
"      Callender TA, Weber RS, Janjan N, et al. Rhabdomyosarcoma of the nose and paranasal sinuses in adults and children. Otolaryngol Head Neck Surg 1995; 112:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/73\">",
"      Prestidge BR, Donaldson SS. Treatment results among adults with childhood tumors: a 20-year experience. Int J Radiat Oncol Biol Phys 1989; 17:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/74\">",
"      Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988; 61:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/75\">",
"      Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993; 71:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/76\">",
"      Raney RB, Asmar L, Vassilopoulou-Sellin R, et al. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. Med Pediatr Oncol 1999; 33:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/77\">",
"      Schouwenburg PF, Kupperman D, Bakker FP, et al. New combined treatment of surgery, radiotherapy, and reconstruction in head and neck rhabdomyosarcoma in children: the AMORE protocol. Head Neck 1998; 20:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/78\">",
"      Albores-Saavedra J, Schwartz AM, Henson DE, et al. Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007. Ann Diagn Pathol 2011; 15:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/79\">",
"      Lydiatt WM, Shaha AR, Shah JP. Angiosarcoma of the head and neck. Am J Surg 1994; 168:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/80\">",
"      Mark RJ, Tran LM, Sercarz J, et al. Angiosarcoma of the head and neck. The UCLA experience 1955 through 1990. Arch Otolaryngol Head Neck Surg 1993; 119:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/81\">",
"      Panje WR, Moran WJ, Bostwick DG, Kitt VV. Angiosarcoma of the head and neck: review of 11 cases. Laryngoscope 1986; 96:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/82\">",
"      Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 1987; 59:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/83\">",
"      Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/84\">",
"      Maddox JC, Evans HL. Angiosarcoma of skin and soft tissue: a study of forty-four cases. Cancer 1981; 48:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/85\">",
"      Morrison WH, Byers RM, Garden AS, et al. Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer 1995; 76:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/86\">",
"      Willers H, Hug EB, Spiro IJ, et al. Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors. Int J Radiat Oncol Biol Phys 1995; 33:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/87\">",
"      Lahat G, Dhuka AR, Hallevi H, et al. Angiosarcoma: clinical and molecular insights. Ann Surg 2010; 251:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/88\">",
"      K&ouml;hler HF, Neves RI, Brechtb&uuml;hl ER, et al. Cutaneous angiosarcoma of the head and neck: report of 23 cases from a single institution. Otolaryngol Head Neck Surg 2008; 139:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/89\">",
"      Aust MR, Olsen KD, Lewis JE, et al. Angiosarcomas of the head and neck: clinical and pathologic characteristics. Ann Otol Rhinol Laryngol 1997; 106:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/90\">",
"      Guadagnolo BA, Zagars GK, Araujo D, et al. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck 2011; 33:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/91\">",
"      Amato L, Moretti S, Palleschi GM, et al. A case of angiosarcoma of the face successfully treated with combined chemotherapy and radiotherapy. Br J Dermatol 2000; 142:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/92\">",
"      Lankester KJ, Brown RS, Spittle MF. Complete resolution of angiosarcoma of the scalp with liposomal daunorubicin and radiotherapy. Clin Oncol (R Coll Radiol) 1999; 11:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/93\">",
"      Young RJ, Brown NJ, Reed MW, et al. Angiosarcoma. Lancet Oncol 2010; 11:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/94\">",
"      DeMartelaere SL, Roberts D, Burgess MA, et al. Neoadjuvant chemotherapy-specific and overall treatment outcomes in patients with cutaneous angiosarcoma of the face with periorbital involvement. Head Neck 2008; 30:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/95\">",
"      Ono S, Tanioka M, Fujisawa A, et al. Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib. Arch Dermatol 2012; 148:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/96\">",
"      Kruse AL, Luebbers HT, Gr&auml;tz KW, Obwegeser JA. Aggressive fibromatosis of the head and neck: a new classification based on a literature review over 40&nbsp;years (1968-2008). Oral Maxillofac Surg 2010; 14:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/97\">",
"      Mark RJ, Bailet JW, Tran LM, et al. Dermatofibrosarcoma protuberans of the head and neck. A report of 16 cases. Arch Otolaryngol Head Neck Surg 1993; 119:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/98\">",
"      Tom WD, Hybarger CP, Rasgon BM. Dermatofibrosarcoma protuberans of the head and neck: treatment with Mohs surgery using inverted horizontal paraffin sections. Laryngoscope 2003; 113:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/99\">",
"      Tan WP, Barlow RJ, Robson A, et al. Dermatofibrosarcoma protuberans: 35 patients treated with Mohs micrographic surgery using paraffin sections. Br J Dermatol 2011; 164:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/100\">",
"      Paradisi A, Abeni D, Rusciani A, et al. Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery. Cancer Treat Rev 2008; 34:728.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/102\">",
"      Kartha SS, Bumpous JM. Synovial cell sarcoma: diagnosis, treatment, and outcomes. Laryngoscope 2002; 112:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/103\">",
"      Ulrich CT, Feiz-Erfan I, Spetzler RF, et al. Sinonasal leiomyosarcoma: review of literature and case report. Laryngoscope 2005; 115:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/104\">",
"      Harb WJ, Luna MA, Patel SR, et al. Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension. Head Neck 2007; 29:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/105\">",
"      Balm AJ, Vom Coevorden F, Bos KE, et al. Report of a symposium on diagnosis and treatment of adult soft tissue sarcomas in the head and neck. Eur J Surg Oncol 1995; 21:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/106\">",
"      Barker JL Jr, Paulino AC, Feeney S, et al. Locoregional treatment for adult soft tissue sarcomas of the head and neck: an institutional review. Cancer J 2003; 9:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/107\">",
"      Le Vay J, O'Sullivan B, Catton C, et al. An assessment of prognostic factors in soft-tissue sarcoma of the head and neck. Arch Otolaryngol Head Neck Surg 1994; 120:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/108\">",
"      Le QT, Fu KK, Kroll S, et al. Prognostic factors in adult soft-tissue sarcomas of the head and neck. Int J Radiat Oncol Biol Phys 1997; 37:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/109\">",
"      Colville RJ, Charlton F, Kelly CG, et al. Multidisciplinary management of head and neck sarcomas. Head Neck 2005; 27:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/110\">",
"      O'Sullivan B, Gullane P, Irish J, et al. Preoperative radiotherapy for adult head and neck soft tissue sarcoma: assessment of wound complication rates and cancer outcome in a prospective series. World J Surg 2003; 27:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/111\">",
"      Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/50/34602/abstract/112\">",
"      Dudhat SB, Mistry RC, Varughese T, et al. Prognostic factors in head and neck soft tissue sarcomas. Cancer 2000; 89:868.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3367 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34602=[""].join("\n");
var outline_f33_50_34602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY, HISTOLOGIC DISTRIBUTION, AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15527574\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION AND DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15528177\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15528479\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15528150\">",
"      NATURAL HISTORY, AND PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15527615\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Histologic grade and tumor size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15527726\">",
"      - Surgical margins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Histologic subtype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8921486\">",
"      - Nodal metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15528788\">",
"      GENERAL TREATMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgical principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adjuvant RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15528780\">",
"      Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15528823\">",
"      SPECIFIC SUBTYPES, CLINICAL PRESENTATION AND TREATMENT RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Natural history and prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2958961\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3299381\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rhabdomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Staging and prognostic stratification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Natural history and prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Overview of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Angiosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Natural history and prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Desmoids and dermatofibrosarcoma protuberans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Other adult soft tissue sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15527453\">",
"      SUMMARY AND RECOMMENDATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25334872\">",
"      Specific histologic subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3367\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3367|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/11/17597\" title=\"table 1\">",
"      Imaging guidelines for newly diagnosed osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/41/32411\" title=\"table 2\">",
"      Clinical group rhabdomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/13/7389\" title=\"table 3\">",
"      Rhabdomyosarcoma TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/52/11086\" title=\"table 4\">",
"      Rhabdomyosarc prognos stratify",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/13/23773\" title=\"table 5\">",
"      2010 TNM staging STS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14521?source=related_link\">",
"      Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=related_link\">",
"      Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=related_link\">",
"      Bone tumors: Diagnosis and biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=related_link\">",
"      Chemotherapy and radiation therapy in the management of osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=related_link\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=related_link\">",
"      Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=related_link\">",
"      Dermatofibrosarcoma protuberans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=related_link\">",
"      Desmoid tumors: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=related_link\">",
"      Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=related_link\">",
"      Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8919?source=related_link\">",
"      Management of acquired maxillary defects: Prosthetic rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39815?source=related_link\">",
"      Mandibular and palatal reconstruction in patients with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18327?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34586?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/11/41146?source=related_link\">",
"      Systemic treatment of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_50_34603="Resp patterns and ABG in Coma";
var content_f33_50_34603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ventilatory and arterial blood gas patterns in coma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Breathing pattern",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolic pattern",
"       </td>",
"       <td class=\"subtitle1\">",
"        pH, PaCO2, HCO3",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperventilation",
"       </td>",
"       <td>",
"        Metabolic acidosis",
"       </td>",
"       <td>",
"        pH &lt;7.3, PaCO2 &lt;30 mmHg, HCO3 &lt;17 mmol/L",
"       </td>",
"       <td>",
"        Uremia, diabetic ketoacidosis, lactic acidosis, salicylates, methanol, ethylene glycol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperventilation",
"       </td>",
"       <td>",
"        Respiratory alkalosis",
"       </td>",
"       <td>",
"        pH &gt;7.45, PaCO2 &lt;30 mmHg, HCO3 &gt;17 mmol/L",
"       </td>",
"       <td>",
"        Hepatic failure, acute sepsis, acute salicylate intoxication, cardiopulmonary states with hypoxemia, psychogenic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoventilation",
"       </td>",
"       <td>",
"        Respiratory acidosis",
"       </td>",
"       <td>",
"        pH &lt;7.35 (if acute), PaCO2 &gt;90 mmHg, HCO3 &gt;17 mmol/L",
"       </td>",
"       <td>",
"        Respiratory failure from central (eg, brain or spinal cord) or peripheral nervous system disease, chest conditions or deformities. Coma only with severe hypercarbia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoventilation",
"       </td>",
"       <td>",
"        Metabolic alkalosis",
"       </td>",
"       <td>",
"        pH&gt; 7.45, PaCO2 &gt;45 mmHg, HCO3 &gt;30 mmol/L",
"       </td>",
"       <td>",
"        Vomiting, alkali ingestion. Usually no impairment of consciousness; if so, suspect psychogenic unresponsiveness or additional cause.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34603=[""].join("\n");
var outline_f33_50_34603=null;
var title_f33_50_34604="DDx Foot ankle pain athlete A";
var content_f33_50_34604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of foot and ankle pain in the young athlete",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of injury",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location of pain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Talar",
"pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OCD talus, posteromedial",
"       </td>",
"       <td>",
"        Inversion with plantarflexion",
"       </td>",
"       <td>",
"        Postermedial talus in dorsiflexion",
"       </td>",
"       <td>",
"        AP view of ankle, maximal plantar flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        OCD talus, anterolateral",
"       </td>",
"       <td>",
"        Inversion with dorsiflexion",
"       </td>",
"       <td>",
"        Anterolateral talus in plantarflexion",
"       </td>",
"       <td>",
"        Mortise view in ankle dorsiflexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stress fracture, talus",
"       </td>",
"       <td>",
"        Chronic stress (running, dancing)",
"       </td>",
"       <td>",
"        Rearfoot pain with activity",
"       </td>",
"       <td>",
"        AP, lateral, and mortise views of ankle; may be better",
"seen with MRI or CT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Lateral",
"ankle pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ankle sprain (lateral ligaments)",
"       </td>",
"       <td>",
"        Inversion of ankle",
"       </td>",
"       <td>",
"        ATFL, PTFL, CFL",
"       </td>",
"       <td>",
"        AP, lateral, and mortise views of ankle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sinus tarsi syndrome",
"       </td>",
"       <td>",
"        Severe, recurrent ankle inversion sprain",
"       </td>",
"       <td>",
"        Lateral ankle (posterior and inferior to ATFL)",
"       </td>",
"       <td>",
"        Stress radiographs of the ankle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Peroneal tendon injuries",
"       </td>",
"       <td>",
"        Acute ankle sprain",
"       </td>",
"       <td rowspan=\"4\">",
"        Peroneal tendons (superior to lateral malleolus)",
"       </td>",
"       <td rowspan=\"4\">",
"        AP, lateral, and mortise views of the ankle (to exclude",
"bony injury); Consider MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic ankle instability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peroneal",
"subluxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Os peroneum",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Lateral plantar cuboid",
"       </td>",
"       <td rowspan=\"2\">",
"        AP, lateral, and mortise views of the ankle; AP,",
"oblique views of the foot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcaneocuboid articulartion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L4 radiculopathy",
"       </td>",
"       <td>",
"        Disc herniation",
"       </td>",
"       <td>",
"        Quadriceps",
"       </td>",
"       <td>",
"        Consider MRI spine (after EMG/NCS)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OCD: osteochondritis dissecans; AP: anteroposterior; MRI: magnetic resonance imaging; CT: computed tomography; ATFL: anterior talofibular ligament; PTFL: posterior talofibular ligament; CFL: calcaneofibular ligament; EMG: electromyography; NCS: nerve conduction studies.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34604=[""].join("\n");
var outline_f33_50_34604=null;
var title_f33_50_34605="Summary of drug-induced acute pancreatitis based on drug class";
var content_f33_50_34605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of drug-induced acute pancreatitis based on drug class",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class Ia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class Ib",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class II",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class III",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         &alpha;-methyldopa",
"        </p>",
"        <p>",
"         Azodisalicylate",
"        </p>",
"        <p>",
"         Bezafibrate",
"        </p>",
"        <p>",
"         Cannabis",
"        </p>",
"        <p>",
"         Carbimazole",
"        </p>",
"        <p>",
"         Codeine",
"        </p>",
"        <p>",
"         Cytosine",
"        </p>",
"        <p>",
"         Arabinoside",
"        </p>",
"        <p>",
"         Dapsone",
"        </p>",
"        <p>",
"         Enalapril",
"        </p>",
"        <p>",
"         Furosemide",
"        </p>",
"        <p>",
"         Isoniazid",
"        </p>",
"        <p>",
"         Mesalamine",
"        </p>",
"        <p>",
"         Metronidazole",
"        </p>",
"        <p>",
"         Pentamidine",
"        </p>",
"        <p>",
"         Pravastatin",
"        </p>",
"        <p>",
"         Procainamide",
"        </p>",
"        <p>",
"         Pyritonol",
"        </p>",
"        <p>",
"         Simvastatin",
"        </p>",
"        <p>",
"         Stibogluconate",
"        </p>",
"        <p>",
"         Sulfamethoxazole",
"        </p>",
"        <p>",
"         Sulindac",
"        </p>",
"        <p>",
"         Tetracycline",
"        </p>",
"        <p>",
"         Valproic acid",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         All-trans-retinoic acid",
"        </p>",
"        <p>",
"         Amiodarone",
"        </p>",
"        <p>",
"         Azathioprine",
"        </p>",
"        <p>",
"         Clomiphene",
"        </p>",
"        <p>",
"         Dexamethasone",
"        </p>",
"        <p>",
"         Ifosfamide",
"        </p>",
"        <p>",
"         Lamivudine",
"        </p>",
"        <p>",
"         Losartan",
"        </p>",
"        <p>",
"         Lynestrenol/methoxyethinylestradiol",
"        </p>",
"        <p>",
"         6-mercaptopurine",
"        </p>",
"        <p>",
"         Meglumine",
"        </p>",
"        <p>",
"         Methimazole",
"        </p>",
"        <p>",
"         Nelfinavir",
"        </p>",
"        <p>",
"         Norethindronate/mestranol",
"        </p>",
"        <p>",
"         Omeprazole",
"        </p>",
"        <p>",
"         Premarin",
"        </p>",
"        <p>",
"         Trimethoprimsulfamethazole",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Acetaminophen",
"        </p>",
"        <p>",
"         Chlorothiazide",
"        </p>",
"        <p>",
"         Clozapine",
"        </p>",
"        <p>",
"         Didanosine",
"        </p>",
"        <p>",
"         Erythromycin",
"        </p>",
"        <p>",
"         Estrogen",
"        </p>",
"        <p>",
"         L-asparaginase",
"        </p>",
"        <p>",
"         Pegaspargase",
"        </p>",
"        <p>",
"         Propofol",
"        </p>",
"        <p>",
"         Tamoxifen",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Alendronate",
"        </p>",
"        <p>",
"         Atorvastatin",
"        </p>",
"        <p>",
"         Carbamazepine",
"        </p>",
"        <p>",
"         Captopril",
"        </p>",
"        <p>",
"         Ceftriaxone",
"        </p>",
"        <p>",
"         Chlorthalidone",
"        </p>",
"        <p>",
"         Cimetidine",
"        </p>",
"        <p>",
"         Clarithromycin",
"        </p>",
"        <p>",
"         Cyclosporin",
"        </p>",
"        <p>",
"         Gold",
"        </p>",
"        <p>",
"         Hydrochlorothiazide",
"        </p>",
"        <p>",
"         Indomethacin",
"        </p>",
"        <p>",
"         Interferon/ribavirin",
"        </p>",
"        <p>",
"         Irbesartan",
"        </p>",
"        <p>",
"         Isotretinoin",
"        </p>",
"        <p>",
"         Ketorolac",
"        </p>",
"        <p>",
"         Lisinopril",
"        </p>",
"        <p>",
"         Metolazone",
"        </p>",
"        <p>",
"         Metformin",
"        </p>",
"        <p>",
"         Minocycline",
"        </p>",
"        <p>",
"         Mirtazapine",
"        </p>",
"        <p>",
"         Naproxen",
"        </p>",
"        <p>",
"         Paclitaxel",
"        </p>",
"        <p>",
"         Ponatinib",
"        </p>",
"        <p>",
"         Prednisone",
"        </p>",
"        <p>",
"         Prednisolone",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Adrenocorticotrophic hormone",
"        </p>",
"        <p>",
"         Ampicillin",
"        </p>",
"        <p>",
"         Bendroflumethiazide",
"        </p>",
"        <p>",
"         Benazepril",
"        </p>",
"        <p>",
"         Betamethasone",
"        </p>",
"        <p>",
"         Capecitabine",
"        </p>",
"        <p>",
"         Cisplatin",
"        </p>",
"        <p>",
"         Colchicine",
"        </p>",
"        <p>",
"         Cyclophosphamide",
"        </p>",
"        <p>",
"         Cyproheptadine",
"        </p>",
"        <p>",
"         Danazol",
"        </p>",
"        <p>",
"         Diazoxide",
"        </p>",
"        <p>",
"         Diclofenac",
"        </p>",
"        <p>",
"         Diphenoxylate",
"        </p>",
"        <p>",
"         Doxorubicin",
"        </p>",
"        <p>",
"         Ethacrynic acid",
"        </p>",
"        <p>",
"         Famciclovir",
"        </p>",
"        <p>",
"         Finasteride",
"        </p>",
"        <p>",
"         5-fluorouracil",
"        </p>",
"        <p>",
"         Fluvastatin",
"        </p>",
"        <p>",
"         Gemfibrozil",
"        </p>",
"        <p>",
"         Interleukin-2",
"        </p>",
"        <p>",
"         Ketoprofen",
"        </p>",
"        <p>",
"         Lovastatin",
"        </p>",
"        <p>",
"         Mefenamic acid",
"        </p>",
"        <p>",
"         Nitrofurantoin",
"        </p>",
"        <p>",
"         Octreotide",
"        </p>",
"        <p>",
"         Oxyphenbutazone",
"        </p>",
"        <p>",
"         Penicillin",
"        </p>",
"        <p>",
"         Phenophthalein",
"        </p>",
"        <p>",
"         Propoxyphene",
"        </p>",
"        <p>",
"         Ramipril",
"        </p>",
"        <p>",
"         Ranitidine",
"        </p>",
"        <p>",
"         Rifampin",
"        </p>",
"        <p>",
"         Risperidone",
"        </p>",
"        <p>",
"         Ritonavir",
"        </p>",
"        <p>",
"         Roxithromycin",
"        </p>",
"        <p>",
"         Rosuvastatin",
"        </p>",
"        <p>",
"         Sertaline",
"        </p>",
"        <p>",
"         Strychnine",
"        </p>",
"        <p>",
"         Tacrolimus",
"        </p>",
"        <p>",
"         Vigabatrin/lamotrigine",
"        </p>",
"        <p>",
"         Vincristine",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Badalov N, Baradarian R, Kadirawel I, et al. Drug-Induced Acute Pancreatitis: An Evidence-Based Review. Clin Gastroenterol Hepatol 2007; 5:648. Copyright &copy; 2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34605=[""].join("\n");
var outline_f33_50_34605=null;
var title_f33_50_34606="Bacterial tracheitis x-ray";
var content_f33_50_34606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bacterial tracheitis: Lateral neck radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral neck radiograph showing intraluminal membranes and tracheal wall irregularity consistent with bacterial tracheitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of R. Paul Guillerman, MD, Department of Radiology, Baylor College of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34606=[""].join("\n");
var outline_f33_50_34606=null;
var title_f33_50_34607="VSD in Tetrology of Fallot parasternal long axis echo";
var content_f33_50_34607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/54225/palaxvsd_conv.mp4?title=VSD+in+Tetrology+of+Fallot+parasternal+long+axis+echo\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ventricular septal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parasternal long axis view from a 2-D echocardiogram with color flow Doppler shows a ventricular septal defect (VSD) of the membraneous septum with left to right shunting of blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_50_34607=[""].join("\n");
var outline_f33_50_34607=null;
